0000http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligationsP0Y440000大型加速存取器錯誤0000錯誤Amphastar Pharmaceuticals, Inc.--12-31錯誤0001297184Q3錯誤YesDE錯誤2024-09-30000P30D0000000001297184us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001297184amph:2014年11月份股票回購計劃成員2024-07-012024-09-300001297184amph:2014年11月份股票回購計劃成員2024-01-012024-09-300001297184us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001297184amph : 2014年11月份股票回購計劃成員2023-07-012023-09-300001297184amph : 2014年11月份股票回購計劃成員2023-01-012023-09-300001297184us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001297184amph : 2014年11月份股票回購計劃成員us-gaap:後續事件會員2024-11-040001297184amph : 2014年11月份股票回購計劃成員2024-06-030001297184us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001297184us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001297184us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001297184US-GAAP:普通股成員2024-07-012024-09-300001297184US-GAAP:普通股成員2024-04-012024-06-300001297184US-GAAP:普通股成員2024-01-012024-03-310001297184US-GAAP:普通股成員2023-07-012023-09-300001297184US-GAAP:普通股成員2023-04-012023-06-300001297184US-GAAP:普通股成員2023-01-012023-03-3100012971842024-06-3000012971842024-03-3100012971842023-06-3000012971842023-03-310001297184us-gaap:留存收益成員2024-09-300001297184美元指數: 應付股本會員2024-09-300001297184us-gaap:其他綜合收益的累計成員2024-09-300001297184us-gaap:留存收益成員2024-06-300001297184美元指數: 應付股本會員2024-06-300001297184us-gaap:其他綜合收益的累計成員2024-06-300001297184us-gaap:留存收益成員2024-03-310001297184美元指數: 應付股本會員2024-03-310001297184us-gaap:其他綜合收益的累計成員2024-03-310001297184us-gaap:留存收益成員2023-12-310001297184美元指數: 應付股本會員2023-12-310001297184us-gaap:其他綜合收益的累計成員2023-12-310001297184us-gaap:留存收益成員2023-09-300001297184美元指數: 應付股本會員2023-09-300001297184us-gaap:其他綜合收益的累計成員2023-09-300001297184us-gaap:留存收益成員2023-06-300001297184美元指數: 應付股本會員2023-06-300001297184us-gaap:其他綜合收益的累計成員2023-06-300001297184us-gaap:留存收益成員2023-03-310001297184美元指數: 應付股本會員2023-03-310001297184us-gaap:其他綜合收益的累計成員2023-03-310001297184us-gaap:留存收益成員2022-12-310001297184美元指數: 應付股本會員2022-12-310001297184us-gaap:其他綜合收益的累計成員2022-12-310001297184amph:2014年員工股票購買計劃成員2024-09-300001297184amph:2015年股權激勵計劃成員2024-09-300001297184美國通用會計原則限制性股票單位累計成員2023-12-310001297184amph:成品藥品部門成員amph:Phytonadione成員2024-07-012024-09-300001297184amph:成品藥品部門成員amph:其他成品藥品成員2024-07-012024-09-300001297184amph:成品藥品部門成員amph:納洛酮成員2024-07-012024-09-300001297184amph:成品藥物產品部門成員amph:利多卡因成員2024-07-012024-09-300001297184amph:成品藥物產品部門成員amph:葡萄糖胰素成員2024-07-012024-09-300001297184amph:成品藥物產品部門成員amph:成品藥物產品淨收入成員2024-07-012024-09-300001297184amph:成品藥物產品部門成員amph: 腎上腺素成員2024-07-012024-09-300001297184amph: 成品藥物產品部門成員amph: 依諾肝素成員2024-07-012024-09-300001297184amph: 成品藥物產品部門成員amph: Baqsimi Neb 成員2024-07-012024-09-300001297184amph: 成品藥物產品部門成員amph: Baqsimi 成員2024-07-012024-09-300001297184amph: Anp 成員amph: 研發服務會員2024-07-012024-09-300001297184amph: Anp會員amph: 南京漢欣製藥技術有限公司會員2024-07-012024-09-300001297184US GAAP: 產品成員2024-07-012024-09-300001297184美國通用會計準則:產品和服務其他成員2024-07-012024-09-300001297184國家:美國2024-07-012024-09-300001297184國家:FR2024-07-012024-09-300001297184國家:CN2024-07-012024-09-300001297184amph:成品藥品部門成員amph:維生素K成員2024-01-012024-09-300001297184amph:成品藥品部門成員amph:其他成品藥品成員2024-01-012024-09-300001297184amph:成品藥品部門成員amph:納洛酮成員2024-01-012024-09-300001297184amph:成品藥品部門成員amph:利多卡因成員2024-01-012024-09-300001297184amph:成品藥品產品部門成員amph:胰高血糖素成員2024-01-012024-09-300001297184amph:成品藥品產品部門成員amph:成品藥品產品淨收入成員2024-01-012024-09-300001297184amph:成品藥品產品部門成員amph:腎上腺素成員2024-01-012024-09-300001297184amph:成品藥品產品部門成員amph:依諾肝素成員2024-01-012024-09-300001297184amph:完整製藥產品部分成員amph:Baqsimi Neb成員2024-01-012024-09-300001297184amph:完整製藥產品部分成員amph:Baqsimi成員2024-01-012024-09-300001297184amph:Anp成員amph:研發服務部門成員2024-01-012024-09-300001297184amph:Anp成員amph:南京瀚鑫製藥科技有限公司成員2024-01-012024-09-300001297184US GAAP: 產品成員2024-01-012024-09-300001297184美國通用會計準則:產品和服務其他成員2024-01-012024-09-300001297184國家:美國2024-01-012024-09-300001297184國家:FR2024-01-012024-09-300001297184國家:CN2024-01-012024-09-300001297184amph:成品藥品部門成員amph:Phytonadione成員2023-07-012023-09-300001297184amph:成品藥品部門成員amph:其他已完成製藥產品成員2023-07-012023-09-300001297184amph:已完成製藥產品部門成員amph:納洛酮成員2023-07-012023-09-300001297184amph:已完成製藥產品部門成員amph:利多卡因成員2023-07-012023-09-300001297184amph:已完成製藥產品部門成員amph:已完成製藥產品淨收入成員2023-07-012023-09-300001297184amph:已完成製藥產品部門成員amph:腎上腺素成員2023-07-012023-09-300001297184amph:成品藥產品部門成員amph:依諾肝素成員2023-07-012023-09-300001297184amph:成品藥產品部門成員amph:Baqsimi Neb成員2023-07-012023-09-300001297184amph:成品藥產品部門成員amph:Baqsimi成員2023-07-012023-09-300001297184amph:Anp成員amph:研究與開發服務會員2023-07-012023-09-300001297184amph:Anp會員amph:南京漢信製藥科技有限公司會員2023-07-012023-09-300001297184US GAAP: 產品成員2023-07-012023-09-300001297184美國通用會計準則:產品和服務其他成員2023-07-012023-09-300001297184國家:美國2023-07-012023-09-300001297184國家:FR2023-07-012023-09-300001297184國家:CN2023-07-012023-09-300001297184amph: 成品製藥產品部門成員amph: 酮哌酮成員2023-01-012023-09-300001297184amph: 成品製藥產品部門成員amph: 其他成品製藥產品成員2023-01-012023-09-300001297184amph: 成品製藥產品部門成員amph: 納洛酮成員2023-01-012023-09-300001297184amph: 成品製藥產品部門成員amph: 利多卡因成員2023-01-012023-09-300001297184amph:成品製藥產品部門成員amph:成品製藥產品淨收入成員2023-01-012023-09-300001297184amph:成品製藥產品部門成員amph:腎上腺素成員2023-01-012023-09-300001297184amph:成品製藥產品部門成員amph:依諾肝素成員2023-01-012023-09-300001297184amph:成品製藥產品部門成員amph:Baqsimi Neb成員2023-01-012023-09-300001297184amph:成品藥產品部門成員amph:Baqsimi成員2023-01-012023-09-300001297184amph:Anp成員amph:研發服務成員2023-01-012023-09-300001297184amph:Anp成員amph:南京瀚鑫藥業技術有限公司成員2023-01-012023-09-300001297184US GAAP: 產品成員2023-01-012023-09-300001297184美國通用會計準則:產品和服務其他成員2023-01-012023-09-300001297184國家:美國2023-01-012023-09-300001297184國家:FR2023-01-012023-09-300001297184國家:CN2023-01-012023-09-300001297184美國通用會計準則:存單成員us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2024-09-300001297184美國通用會計準則:存單成員us-gaap:重複計量公允價值會員2024-09-300001297184美國通用會計準則:存單成員us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2023-12-310001297184美國通用會計準則:存單成員us-gaap:重複計量公允價值會員2023-12-310001297184amph:南京翰新制藥科技有限公司會員2024-07-012024-09-300001297184amph:南京樂拓醫療科技有限公司會員2024-01-012024-09-300001297184amph:南京樂拓醫療科技有限公司會員2023-07-012023-09-300001297184amph: 南京漢信製藥科技有限公司會員2023-07-012023-09-300001297184amph: 南京樂拓醫療科技有限公司會員2023-01-012023-09-300001297184amph: 南京漢信製藥科技有限公司會員2023-01-012023-09-300001297184amph: 南京樂拓醫療科技有限公司會員2022-11-012022-11-300001297184美國通用會計準則:機械設備成員2024-09-300001297184us-gaap:租賃改善會員2024-09-300001297184美國通用會計準則:土地成員2024-09-300001297184在建工程2024-09-300001297184us-gaap:建築成員2024-09-300001297184amph:傢俱,設備和車輛成員2024-09-300001297184美國通用會計準則:機械設備成員2023-12-310001297184us-gaap:租賃改善會員2023-12-310001297184美國通用會計準則:土地成員2023-12-310001297184在建工程2023-12-310001297184us-gaap:建築成員2023-12-310001297184amph:傢俱,設備和車輛成員2023-12-310001297184amph:Baqsimi收購會員2024-06-012024-06-300001297184amph:Anp會員amph:南京瀚鑫藥業科技股份有限公司會員2024-09-300001297184amph:南京樂泰醫療科技有限公司會員2024-09-300001297184amph:南京瀚鑫藥業科技股份有限公司會員2024-09-300001297184us-gaap:其他綜合收益的累計成員2024-07-012024-09-300001297184us-gaap:其他綜合收益的累計成員2024-04-012024-06-300001297184us-gaap:其他綜合收益的累計成員2024-01-012024-03-310001297184us-gaap:其他綜合收益的累計成員2023-07-012023-09-300001297184us-gaap:其他綜合收益的累計成員2023-04-012023-06-300001297184us-gaap:其他綜合收益的累計成員2023-01-012023-03-310001297184國家:美國2024-09-300001297184國家:FR2024-09-300001297184國家:CN2024-09-300001297184國家:美國2023-12-310001297184國家:FR2023-12-310001297184國家:CN2023-12-310001297184us-gaap:留存收益成員2024-07-012024-09-300001297184us-gaap:留存收益成員2024-04-012024-06-300001297184us-gaap:留存收益成員2024-01-012024-03-310001297184us-gaap:留存收益成員2023-07-012023-09-300001297184us-gaap:留存收益成員2023-04-012023-06-300001297184us-gaap:留存收益成員2023-01-012023-03-310001297184amph:承諾購買設備和原材料會員2024-07-012024-09-300001297184us-gaap: 循環信貸設施成員amph:到期日2026年8月的循環信用額度會員amph:Capital One National Association會員2024-09-300001297184美國公認會計原則:授信額度成員amph:到期日2021年8月的信用額度會員amph:招商銀行會員2024-09-300001297184amph:到期日2028年6月的貸款會員amph:富國銀行會員2024-09-300001297184amph:法國政府貸款4到期日2026年12月會員amph:塞納諾曼底水務局會員2024-09-300001297184us-gaap: 循環信貸設施成員amph:2026年8月到期的循環信用額度會員amph:美國Capital One國家協會會員2023-12-310001297184美國公認會計原則:授信額度成員amph:2021年8月到期的信用額度會員amph:中國招商銀行會員2023-12-310001297184Amphastar Pharmaceuticals:2028年6月到期的貸款成員Amphastar Pharmaceuticals:富國銀行成員2023-12-310001297184Amphastar Pharmaceuticals:2027年6月到期的應付抵押貸款成員Amphastar Pharmaceuticals:東西銀行成員2023-12-310001297184Amphastar Pharmaceuticals:2026年12月到期的法國政府貸款4成員Amphastar Pharmaceuticals:塞納諾曼底水務局成員2023-12-310001297184Amphastar Pharmaceuticals:2029年到期的二%可轉換優先票據成員2023-12-310001297184Amphastar Pharmaceuticals:財產和意外索賠成員us-gaap:有待解決的訴訟成員2024-09-300001297184美國公認會計原則:授信額度成員amph:2033年11月到期的授信額度成員amph:工商銀行成員2024-01-310001297184us-gaap:TrademarksMember2024-09-300001297184us-gaap:TrademarksMember2023-12-310001297184amph:短期企業債券成員2024-09-300001297184美國通用會計準則:市政債券成員2023-12-310001297184美國公認會計原則:公司債券證券成員2023-12-310001297184amph:企業債券短期會員2023-12-3100012971842023-01-012023-12-310001297184amph:成品藥品部門會員2024-09-300001297184amph:成品藥品部門會員2023-12-310001297184財產使用權成員2024-09-300001297184專利成員2024-09-300001297184amph:Baqsimi收購會員2024-09-300001297184us-gaap:UseRightsMember2023-12-310001297184專利成員2023-12-310001297184amph:Baqsimi收購成員2023-12-310001297184amph:員工顧問和董事股票期權成員2024-09-300001297184amph:員工顧問和董事股票期權成員2024-01-012024-09-300001297184 us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2024-09-300001297184 us-gaap:重複計量公允價值會員2024-09-300001297184 us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2023-12-310001297184 us-gaap:重複計量公允價值會員2023-12-310001297184amph:成品藥品部門成員2024-07-012024-09-300001297184amph:活性藥品成分部門成員2024-07-012024-09-300001297184amph:成品藥物產品部門成員2024-01-012024-09-300001297184amph:活性藥物成分部門成員2024-01-012024-09-300001297184amph:成品藥物產品部門成員2023-07-012023-09-300001297184amph:活性藥物成分部門成員2023-07-012023-09-300001297184amph:成品藥物產品部門成員2023-01-012023-09-300001297184amph:活性藥物成分部門成員2023-01-012023-09-300001297184美國公認會計原則:授信額度成員amph:2033年11月到期的授信額度amph:工商銀行會員2024-09-300001297184amph:百分之二可轉換優先票據截至2029年會員2024-09-300001297184amph:百分之二可轉換優先票據截至2029年會員2023-09-120001297184amph:麥克森會員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-07-012024-09-300001297184amph:Eli Lilly And Co 會員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-07-012024-09-300001297184amph:Cencora 成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-07-012024-09-300001297184amph:Cardinal Health 成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-07-012024-09-300001297184amph:Mc Kesson 成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:麥克森成員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:禮來公司成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Eli Lilly和Co成員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Cencora成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Cencora成員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Cardinal Health成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Cardinal Health成員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2024-01-012024-09-300001297184amph:Mc Kesson成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-07-012023-09-300001297184amph: 艾禮莉安德公司成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-07-012023-09-300001297184amph: Cencora公司成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-07-012023-09-300001297184amph:Cardinal Health 會員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-07-012023-09-300001297184amph:McKesson 會員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2023-01-012023-12-310001297184amph:Eli Lilly And Co 會員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2023-01-012023-12-310001297184amph:Cencora會員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2023-01-012023-12-310001297184amph:Cardinal Health會員us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2023-01-012023-12-310001297184amph:Mc Kesson會員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-01-012023-09-300001297184amph:Eli Lilly And Co成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-01-012023-09-300001297184amph:Cencora成員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-01-012023-09-300001297184amph:心臟健康會員美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-01-012023-09-300001297184us-gaap:TreasuryStockCommonMember2024-09-300001297184US-GAAP:普通股成員2024-09-300001297184us-gaap:TreasuryStockCommonMember2024-06-300001297184US-GAAP:普通股成員2024-06-300001297184us-gaap:TreasuryStockCommonMember2024-03-310001297184US-GAAP:普通股成員2024-03-310001297184us-gaap:TreasuryStockCommonMember2023-12-310001297184US-GAAP:普通股成員2023-12-310001297184us-gaap:TreasuryStockCommonMember2023-09-300001297184US-GAAP:普通股成員2023-09-300001297184us-gaap:TreasuryStockCommonMember2023-06-300001297184US-GAAP:普通股成員2023-06-300001297184us-gaap:TreasuryStockCommonMember2023-03-310001297184US-GAAP:普通股成員2023-03-310001297184us-gaap:TreasuryStockCommonMember2022-12-310001297184US-GAAP:普通股成員2022-12-310001297184美國通用會計準則:貨幣市場基金成員美國通用會計準則: 公允價值輸入一級成員us-gaap:重複計量公允價值會員2024-09-300001297184美國通用會計準則:貨幣市場基金成員us-gaap:重複計量公允價值會員2024-09-300001297184美國通用會計準則:貨幣市場基金成員美國通用會計準則: 公允價值輸入一級成員us-gaap:重複計量公允價值會員2023-12-310001297184美國通用會計準則:貨幣市場基金成員us-gaap:重複計量公允價值會員2023-12-310001297184amph: Baqsimi併購成員2023-04-210001297184us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2024-09-300001297184美國通用會計準則: 公允價值輸入一級成員us-gaap:重複計量公允價值會員2024-09-300001297184us-gaap:重複計量公允價值會員2024-09-300001297184us-gaap:公允價值輸入二級成員us-gaap:重複計量公允價值會員2023-12-310001297184美國通用會計準則: 公允價值輸入一級成員us-gaap:重複計量公允價值會員2023-12-310001297184us-gaap:重複計量公允價值會員2023-12-310001297184amph:Baqsimi 收購成員2023-04-212023-04-210001297184amph:員工和非員工股票期權成員2023-07-012023-09-300001297184us-gaap:銷售和營銷費用2024-07-012024-09-300001297184美國通用會計原則限制性股票單位累計成員2024-07-012024-09-300001297184us-gaap:研發支出成員2024-07-012024-09-300001297184US-GAAP:一般和管理費用成員2024-07-012024-09-300001297184us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001297184美國通用會計準則:銷售成本成員2024-07-012024-09-300001297184amph:2014年員工股票購買計劃會員2024-07-012024-09-300001297184us-gaap:銷售和營銷費用2024-01-012024-09-300001297184美國通用會計原則限制性股票單位累計成員2024-01-012024-09-300001297184us-gaap:研發支出成員2024-01-012024-09-300001297184US-GAAP:一般和管理費用成員2024-01-012024-09-300001297184us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001297184美國通用會計準則:銷售成本成員2024-01-012024-09-300001297184amph:2014年員工股票購買計劃會員2024-01-012024-09-300001297184us-gaap:銷售和營銷費用2023-07-012023-09-300001297184美國通用會計原則限制性股票單位累計成員2023-07-012023-09-300001297184us-gaap:研發支出成員2023-07-012023-09-300001297184US-GAAP:一般和管理費用成員2023-07-012023-09-300001297184us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001297184美國通用會計準則:銷售成本成員2023-07-012023-09-300001297184amph: 2014年員工股票購買計劃成員2023-07-012023-09-300001297184us-gaap:銷售和營銷費用2023-01-012023-09-300001297184美國通用會計原則限制性股票單位累計成員2023-01-012023-09-300001297184us-gaap:研發支出成員2023-01-012023-09-300001297184US-GAAP:一般和管理費用成員2023-01-012023-09-300001297184us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001297184美國通用會計準則:銷售成本成員2023-01-012023-09-300001297184amph:Employee Stock Purchase Plan 2014成員2023-01-012023-09-300001297184amph:Finished Pharmaceutical Products Segment成員amph:Primatenemist成員2024-07-012024-09-300001297184amph:已完成製藥產品部門成員amph:Primaltenemist會員2024-01-012024-09-300001297184amph:已完成製藥產品部門成員amph:Primaltenemist會員2023-07-012023-09-300001297184amph:已完成製藥產品部門成員amph:Primaltenemist會員2023-01-012023-09-300001297184amph:2014年11月回購計劃成員2024-11-0400012971842024-11-010001297184美元指數: 應付股本會員2024-07-012024-09-300001297184美元指數: 應付股本會員2024-04-012024-06-3000012971842024-04-012024-06-300001297184美元指數: 應付股本會員2024-01-012024-03-3100012971842024-01-012024-03-310001297184美元指數: 應付股本會員2023-07-012023-09-300001297184美元指數: 應付股本會員2023-04-012023-06-3000012971842023-04-012023-06-300001297184美元指數: 應付股本會員2023-01-012023-03-3100012971842023-01-012023-03-310001297184美國通用會計原則限制性股票單位累計成員2024-09-300001297184amph : Restricted Stock Units Issued As Compensation Member2024-01-012024-09-300001297184us-gaap:AccountsReceivableMember2024-09-300001297184us-gaap:應付賬款及應計負債成員2024-09-300001297184us-gaap:AccountsReceivableMember2023-12-310001297184us-gaap:應付賬款及應計負債成員2023-12-3100012971842023-09-3000012971842022-12-310001297184srt:最低會員2024-01-012024-09-300001297184srt:最大成員2024-01-012024-09-300001297184amph:南京瀚鑫醫藥科技有限公司成員2024-01-012024-09-300001297184us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-07-012024-09-300001297184美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2024-01-012024-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2024-01-012024-09-300001297184美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-07-012023-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:客戶集中度風險成員2023-01-012023-12-310001297184美國通用會計準則:淨銷售收入會員us-gaap:客戶集中度風險成員2023-01-012023-09-3000012971842024-07-012024-09-3000012971842023-07-012023-09-300001297184 2024-07-012024-09-300001297184 2024-01-012024-09-300001297184 2023-07-012023-09-300001297184 2023-01-012023-09-300001297184amph:員工股票購買計劃2014會員2024-05-012024-05-3100012971842023-01-012023-09-300001297184amph:Baqsimi收購成員2024-01-012024-09-300001297184amph:Baqsimi收購成員2023-07-012023-09-300001297184amph:Baqsimi收購成員2023-01-012023-09-300001297184amph:2029年到期的兩厘可轉換高級票據成員2023-09-300001297184amph:2029年到期的兩厘可轉換高級票據成員2023-09-012023-09-300001297184amph:2029年到期的兩厘可轉換高級票據成員2023-09-122023-09-120001297184美國公認會計原則:授信額度成員amph:截至2033年11月的授信額度成員amph:工商銀行成員2024-01-012024-09-300001297184amph:Baqsimi收購成員2023-06-302023-06-300001297184amph:僱員和非僱員股票期權成員2024-07-012024-09-300001297184amph:僱員和非僱員股票期權成員2024-01-012024-09-300001297184amph:僱員和非僱員股票期權成員2023-01-012023-09-300001297184srt:最大成員amph:Baqsimi收購成員amph:過渡服務協議成員2023-06-302023-06-300001297184srt:最大成員amph: Baqsimi Acquisitions Memberamph: Manufacturing Services Agreement Member2023-06-302023-06-3000012971842024-01-012024-09-3000012971842024-09-3000012971842023-12-31iso4217:USDiso4217:USDxbrli:股份xbrli:純形amph:Damph:物品xbrli:股份amph:分段

目錄

美國

證券交易委員會

華盛頓特區20549

表格 10-Q

季度報告 根據1934年證券交易所法案第13或15(d)條的規定

季度期間 截至9月30日結束 2024

or

過渡報告 根據1934年證券交易所法案第13或15(d)條規定

對於從             到             的過渡期

佣金文件號 001-36509

Amphastar Pharmaceuticals股份有限公司

(根據其章程規定的準確名稱)

特拉華州

 

33-0702205

(國家或其他管轄區的

公司成立或組織)

 

(IRS僱主
唯一識別號碼)

11570 6th

 

Rancho Cucamonga, 加利福尼亞州

 

91730

,(主要行政辦公地址)

(郵政編碼)

(909) 980-9484

(註冊人電話號碼,包括區號)

請用複選標記表示,報告人(1)在前12個月內是否已提交證券交易法1934年第13或第15(d)條規定需要提交的所有報告(或對於要求報告的較短期間,是否已提交這些報告),以及(2)在過去90天內是否一直受到這些報告要求的約束。Yes   沒有

請用複選標記指示,公司是否在過去12個月內(或公司被要求提交這些文件的較短期間內)根據S-t規則(本章第232.405條)已經以電子方式提交了每份交互式數據文件。Yes   沒有

請勾選標記以說明註冊人是大型快速申報人、加速申報人、非加速申報人、較小的報告公司還是新興成長型公司。請查看《交易所法》第120億.2條中「大型快速申報人」、「加速申報人」、「較小的報告公司」和「新興成長型公司」的定義。

大型加速文件申報人

加速文件提交人

非加速文件提交人

更小的報告公司

新興成長公司

如果一張 新興成長性公司如果註冊人選擇不使用根據《證券交易法》第13(a)條規定提供的有關遵守任何新的或修訂的財務會計準則的延長過渡期,請用複選標記指示。

請勾選以下內容。申報人是否是外殼公司(根據證券交易法規則12b-2定義)。    是      No  

在法案第12(b)條的規定下注冊的證券:

T

每一類的名稱

交易標誌

在其上註冊的交易所的名稱

普通股,每股面值爲$0.0001

AMPH

The 納斯達克證券交易所 LLC

2024年11月1日,註冊人唯一一類普通股的流通股數爲 48,081,433.

目錄

amphastar pharmaceuticals, INC。

目 錄

表格 10-Q 期至2024年9月30日止季度

關於前瞻性陳述的特別說明

第一部分 基本報表資料

頁碼

項目 1. 基本報表(未經查核):

2024年9月30日和2023年12月31日的總體資產負債表摘要

1

截至2024年9月30日和2023年,簡明綜合損益表

2

截至2024年和2023年9月30日三個月和九個月的綜合收益簡明合併財務報表

3

截至2024年9月30日和2023年控制項股東權益簡明股東權益表

4

截至2024年和2023年9月30日九個月的綜合現金流量簡明合併財務報表

5

基本報表註記

6

項目2. 管理層對財務狀況和營運結果的討論與分析。

32

項目3. 關於市場風險的定性和定量披露

44

第四項。控制和程序

44

第二部分. 其他資訊

項目1. 法律訴訟

45

第1A項。風險因素

45

第 2 項。未註冊的股票發行和款項使用

46

第三項。優先證券拖欠。

46

第4項。礦山安全披露。

46

項目5。其他信息。

47

項目6. 附件

47

簽名

48

目錄

關於前瞻性陳述的特別說明S

本Form 10-Q季度報告或季度報告包含涉及重大風險和不確定性的「前瞻性陳述」。在某些情況下,您可以通過以下字詞識別前瞻性陳述:“可能,” “可能會,” “將,” “可以,” “應該,” “預期,” “打算,” “計劃,” “預料,” “相信,” “估計,” “預測,” “投影,” “潛在,” “持續,” “進行中” 或這些術語的否定形式或其他可比較的術語,儘管並非所有前瞻性陳述都包含這些識別字詞。前瞻性陳述涉及未來事件、未來財務表現或狀況,並涉及已知和未知的風險、不確定性和其他因素,可能導致實際結果、活動水平、表現或成就與前瞻性陳述所指的內容有實質不同。這些前瞻性陳述包括但不限於有關的聲明:

我們對產品的銷售和市場營銷的期望;
我們對BAQSIMI的期望®,包括我們增加營業收入的能力以及因收購BAQSIMI而獲得某些好處的能力®;
我們成功收購和整合資產的能力,包括整合BAQSIMI的能力®;
我們對製造和生產的期望以及我們產品供應鏈的完整性,包括與我們單一來源供應商相關的風險
我們的業務和營運一般,包括:俄烏和中東衝突以及艱困的宏觀經濟環境對我們的業務、財務狀況、營運、現金流和流動性的不良影響;
我們吸引、僱用和留住高技能人員的能力;
由於自然災害等我們無法控制的原因導致的生產和製造中斷,如停電、大流行病、戰爭、恐怖襲擊或其他事件;
全球、國家和地方經濟和市場條件,特別涉及地緣政治不確定性,包括俄烏和中東衝突、通脹和高利率;
美國食品和藥物管理局(FDA)批准和規管我們產品候選藥物、製造活動和產品營銷活動的時間和可能性;
我們將產品候選藥物在我們平台上推進至成功完成的臨床試驗,以及我們隨後成功商業化我們的產品候選藥物的能力;
成本和延誤來自於我們所受的廣泛製藥監管;
我們在產品開發和營銷方面的競爭能力;
我們對於我們的中國子公司安发匠江藥業有限公司(ANP)業務的期望;
對環境、健康和安全以及其他法律法規對我們業務的不利應用的潛在影響;
我們對於我們新產品和專利藥物輸送技術以及我們的原料藥(API)客戶的市場接受度的期望;
醫藥法規改革和藥品價格、醫療費用報销和覆蓋範圍減少的影響;
我們對從第三方支付者獲得保險覆蓋和適當退款的期望;
價格優惠的金額或供應商的排除對不利影響我們的業務;
知識產權法律的變化,我們建立和維護產品的知識產權保護能力以及在涉嫌侵權案件中成功捍衛我們的知識產權;
我們業務策略、產品開發策略和科技利用的實施;
可能面臨產品責任索賠的風險;
我們成功參與合適的收購目標或許可機會,或完成並整合收購、出售或投資,包括此類收購、出售或投資的預期收益能力;
我們擴展國際業務的能力;
經濟和行業趨勢以及趨勢分析;
我們在美國和國際上業務適用或將適用的法律和法規的遵循能力;
貿易關稅、出口或進口限制或其他貿易壁壘的影響;
患者保護和平價法案(經修訂)以及我們所在國家的其他立法和監管醫療保健改革對我們的影響,包括可能的藥品價格管制;
全球和國內稅收改革的影響;
我們在我們ANP和Amphastar設施的新建築完成和驗證的時間;
股份回購的時間和程度;以及
我們的財務運營預期,包括我們對我們的堆積,營業收入,營業成本,毛利潤或毛利率,營業費用,包括研發、銷售和市場營銷以及總務費用的變化的期望,以及我們實現和保持未來盈利能力的能力。

目錄

您應該完整閱讀此季度報告以及本季度報告中其他地方參考的文件,並應理解,我們的實際結果可能與我們預期的前瞻性陳述所表達或暗示的有實質不同。鑒於我們的前瞻性陳述所受的重大風險和不確定性,您不應過度依賴或將這些陳述視為我們或任何其他人將在任何特定時間範圍內完全實現我們的目標和計劃的陳述或保證。我們在本季度報告中以及在截至2023年12月31日的年度報告(Form 10-k)的第Item 1A.“風險因素”中詳細討論了許多這些風險和不確定性。這些前瞻性陳述僅代表我們對於本季度報告日期的評估和假設,不論本季度報告的交付時間,這些信息可能受到限制或不完整,我們的陳述不應被解讀為表明我們已對所有可能已獲得的相關信息進行了彻底的調查或審查。除非法律要求,我們不承諾在本季度報告日期之後根據新信息、未來事件或其他情況更新或修訂任何前瞻性陳述。

除非明示指示或情境需要,本季度報告中對“amphastar pharmaceuticals”、“該公司”、“我們”、“我們的”和“我們”等引用均指的是amphastar pharmaceuticals公司及其附屬公司。

目錄

財務報表第一部分

項目 1. 基本報表

amphastar pharmaceuticals, INC.

縮表合併資產負債表

(以千為單位,股份數據除外)

    

九月三十日

    

12月31日

2024

2023

(未經審計)

資產

流動資產:

現金及現金等價物

$

192,116

$

144,296

限制性現金

235

235

短期投資

58,375

112,510

受限制的短期投資

 

2,200

 

2,200

應收帳款淨額

 

139,635

 

114,943

存貨

 

130,316

 

105,833

收入稅款退款與存款

 

5,349

 

526

預付費用及其他資產

 

17,723

 

9,057

全部流動資產

 

545,949

 

489,600

不動產、廠房及設備,扣除折舊及攤銷後淨值

 

295,384

 

282,746

融資租賃使用權資產

426

564

營運租賃權使用資產

31,708

32,333

遞延所得稅資產

527

商譽和無形資產,淨值

 

594,796

 

613,295

長期投資

14,685

其他資產

 

23,663

 

25,910

递延税款贷项

 

53,252

 

53,252

資產總額

$

1,545,178

$

1,512,912

負債和股東權益

流動負債:

應付款及應計費用

$

153,268

$

93,366

BAQSIMI的應付款項已計提® (見第3條注釋)

126,090

應納所得稅款

 

1,281

 

1,609

長期債務的當期償還

 

252

 

436

營運租賃負債的流動部分

4,209

3,906

流動負債合計

 

159,010

 

225,407

長期預留所得稅負債

 

6,066

 

6,066

長期債務,扣除當期部分和未攤銷的債券發行成本

 

596,446

 

589,579

長期營運租賃負債,扣除當期部分

28,941

29,721

其他長期負債

 

27,037

 

22,718

總負債

 

817,500

 

873,491

合約和可能負債

股東權益:

優先股: 面額 $0.0001; 20,000,000 已授權股份;無發行並流通中的股份

 

 

普通股: 面額 $0.0001; 300,000,000 授權股份為 60,690,07648,372,997 截至2024年9月30日和2024年12月31日分別發行和流通的股份分別為 59,390,19448,068,881 截至2023年12月31日發行和流通的股份分別為

 

6

 

6

資本公積額額外增資

 

496,427

 

486,056

保留收益

 

530,823

 

409,268

累積其他全面損失

 

(8,821)

 

(8,478)

庫藏股

 

(290,757)

 

(247,431)

總股本

727,678

639,421

負債和股東權益總額

$

1,545,178

$

1,512,912

請參閱附表的簡明綜合基本報表附註

-1-

目錄

amphastar pharmaceuticals, INC。

採計簡明綜合營運報表S

(未經審計; 以千為單位,除每股數據外)

三個月結束了

截至九個月

 

九月三十日

九月三十日

    

2024

    

2023

    

2024

    

2023

 

凈收益:

產品收入淨額

$

188,819

$

151,855

$

525,836

$

437,589

其他收入

2,395

28,701

19,608

28,701

總凈收益

191,214

180,556

545,444

466,290

銷售成本

 

89,273

72,153

258,237

211,309

毛利潤

 

101,941

 

108,403

 

287,207

 

254,981

營業費用:

銷售、分銷和行銷

 

8,995

6,407

27,378

20,234

總務與行政

 

14,821

12,654

43,782

38,418

研發費用

 

21,077

16,664

55,772

53,322

營業費用總計

 

44,893

 

35,725

 

126,932

 

111,974

營業收入

 

57,048

 

72,678

 

160,275

 

143,007

非經營性收入(費用):

利息收入

 

2,427

1,202

8,320

3,156

利息費用

 

(6,698)

(13,702)

(23,918)

(17,702)

其他收入(費用),淨值

 

(5,094)

3,459

1,125

1,553

非營業收入(費用),淨額

 

(9,365)

 

(9,041)

 

(14,473)

 

(12,993)

稅前收入

 

47,683

 

63,637

 

145,802

 

130,014

所得稅負擔

 

7,254

14,025

23,674

27,160

在未經合併聯屬公司損失之前的收入

40,429

49,612

122,128

102,854

未納入關聯公司損失的股權

(390)

(573)

(1,476)

凈利潤

$

40,429

$

49,222

$

121,555

$

101,378

每股淨利潤:

基礎

$

0.83

$

1.01

$

2.50

$

2.10

稀釋

$

0.78

$

0.91

$

2.32

$

1.91

用於計算每股凈利潤的加權平均股份:

基礎

 

48,621

48,701

48,580

48,368

稀釋

 

51,862

53,921

52,307

52,997

請參閱附表的簡明綜合基本報表附註

-2-

目錄

安帕斯塔製藥股份有限公司

簡明綜合綜合收益報表

(未經審核;以千計)

三個月結束

截止九個月

九月三十日

九月三十日

    

2024

    

2023

    

2024

    

2023

 

淨收入

$

40,429

$

49,222

$

121,555

$

101,378

其他綜合收益(虧損),除所得稅

外幣轉換調整

 

5

(87)

 

(343)

213

其他綜合收益總額(虧損)

 

5

 

(87)

 

(343)

 

213

綜合收益總額

$

40,434

$

49,135

$

121,212

$

101,591

請參閱簡明綜合財務報表附註。

-3-

目錄

AMPHASTAR藥品公司。

股東權益簡明合併財務報表

(未經審核;以千為單位,股數除外)

普通股

累計

庫藏股

額外的

其他

實收資本

保留收益

綜合

股份

金額

資本

累積盈餘

收入(損失)

股份

金額

總計

2023年12月31日的結餘

 

59,390,194

$

6

$

486,056

$

409,268

$

(8,478)

 

(11,321,313)

$

(247,431)

$

639,421

凈利潤

 

 

 

 

43,177

 

 

 

 

43,177

其他全面損失

 

 

 

 

 

(291)

 

 

 

(291)

普益公司股權計劃相關之庫藏股發行

(33)

2,197

33

與公司的股本計劃相關聯的普通股發行

 

770,265

 

 

(17,311)

 

 

 

 

 

(17,311)

股份報酬費用

 

 

 

7,360

 

 

 

 

 

7,360

截至2024年3月31日的賬戶餘額

 

60,160,459

$

6

$

476,072

$

452,445

$

(8,769)

 

(11,319,116)

$

(247,398)

$

672,356

凈利潤

 

 

 

 

37,949

 

 

 

 

37,949

其他全面損失

 

 

 

 

 

(57)

 

 

 

(57)

買回庫藏股

 

 

 

 

 

 

(207,288)

(8,498)

 

(8,498)

有關公司權益計劃的庫藏股發行

 

 

(97)

 

 

 

6,363

97

 

發行普通股與公司的股本計劃相關

 

321,996

 

 

5,816

 

 

 

 

 

5,816

股份報酬費用

 

 

 

5,780

 

 

 

 

 

5,780

2024年6月30日賬面結餘

 

60,482,455

$

6

$

487,571

$

490,394

$

(8,826)

 

(11,520,041)

$

(255,799)

$

713,346

凈利潤

 

 

 

 

40,429

 

 

 

 

40,429

其他綜合收益

 

 

 

 

 

5

 

 

 

5

買回庫藏股

 

 

 

 

 

 

(797,038)

(34,958)

 

(34,958)

發行普通股與公司股權計劃相關

 

207,621

 

 

3,260

 

 

 

 

 

3,260

股份報酬費用

 

 

 

5,596

 

 

 

 

 

5,596

2024年9月30日結餘

 

60,690,076

$

6

$

496,427

$

530,823

$

(8,821)

 

(12,317,079)

$

(290,757)

$

727,678

普通股

累計

庫藏股

額外的

其他

實收資本

保留收益

綜合

股份

金額

資本

累積盈餘

收入(損失)

股份

金額

總計

2022年12月31日結餘

 

58,110,231

$

6

$

455,077

$

271,723

$

(8,624)

 

(9,998,162)

$

(189,524)

$

528,658

凈利潤

 

 

 

 

26,032

 

 

 

 

26,032

其他綜合收益

 

 

 

 

 

356

 

 

 

356

買回庫藏股

 

 

 

 

 

 

(263,131)

(8,015)

 

(8,015)

公司股權計劃相關的普通股發行

 

330,300

 

 

(4,565)

 

 

 

 

 

(4,565)

股份報酬費用

 

 

 

6,111

 

 

 

 

 

6,111

截至2023年3月31日的餘額

 

58,440,531

$

6

$

456,623

$

297,755

$

(8,268)

 

(10,261,293)

$

(197,539)

$

548,577

凈利潤

 

 

 

 

26,124

 

 

 

 

26,124

其他全面損失

 

 

 

 

 

(56)

 

 

 

(56)

買回庫藏股

 

 

 

 

 

 

(3,585)

(129)

 

(129)

根據公司股權計劃,發行庫藏股

 

 

(231)

 

 

 

15,207

231

 

為公司的股權計劃發行普通股份

 

627,946

 

 

9,853

 

 

 

 

 

9,853

股份報酬費用

 

 

 

4,865

 

 

 

 

 

4,865

截至2023年6月30日的餘額

 

59,068,477

$

6

$

471,110

$

323,880

$

(8,324)

 

(10,249,671)

$

(197,437)

$

589,235

凈利潤

 

 

 

 

49,222

 

 

 

 

49,222

其他全面損失

 

 

 

 

 

(87)

 

 

 

(87)

買回庫藏股

 

 

 

 

 

 

(1,072,041)

(50,000)

 

(50,000)

與公司的股權計劃相關的普通股發行

 

151,701

 

 

2,126

 

 

 

 

 

2,126

股份報酬費用

 

 

 

4,644

 

 

 

 

 

4,644

2023年9月30日的餘額

 

59,220,178

$

6

$

477,880

$

373,102

$

(8,411)

 

(11,321,712)

$

(247,437)

$

595,140

請參閱附表的簡明綜合基本報表附註

-4-

目錄

amphastar pharmaceuticals, INC.

現金流量表簡明綜合報表S

(未經審核;以千為單位)

截至九個月

九月三十日

    

2024

    

2023

營運活動之現金流量:

凈利潤

$

121,555

$

101,378

調整為運營活動提供的凈現金:

不可重複的資產處置損失

 

110

 

474

長壽資產的損耗

2,700

利率掉期和外匯交易的損益,淨額

1,496

(1,019)

固定資產(包括土地、廠房及設備)折舊

 

20,992

 

18,559

產品權利、商標和專利攤銷

 

18,539

 

6,651

營業租賃使用權資產攤銷

3,010

2,778

折扣、溢價和債務發行成本的攤銷

5,308

8,486

未納入關聯公司損失的股權

573

1,476

股份報酬費用

 

18,736

 

15,620

營運資產和負債的變化:

應收帳款淨額

 

(24,577)

 

(30,175)

存貨

 

(24,329)

 

(6,537)

預付費用及其他資產

 

(10,489)

 

105

所得稅退稅、存款及應付款、淨額

 

(5,147)

 

25,185

營業租賃負債

(2,866)

(2,667)

應付款及應計費用

 

61,451

 

16,625

經營活動產生的淨現金流量

 

184,362

 

159,639

投資活動現金流量:

BAQSIMI® 併購(見註3)

 

(129,000)

 

(506,406)

物業、廠房及設備的購買和施工

 

(28,630)

 

(28,724)

購買投資

(47,507)

(52,802)

到期投資

118,538

38,801

存款及其他資產

 

(2,653)

 

3,064

投資活動中使用的淨現金

 

(89,252)

 

(546,067)

來自融資活動的現金流量:

股權計劃的款項,扣除預扣稅款後的淨額

 

(8,234)

 

7,414

買回庫藏股

 

(43,456)

 

(58,144)

債務發行成本

(838)

(24,589)

來自授信額度借款的收入

 

13,565

 

發行長期債務證券所得

 

 

845,000

長期債務本金償還

 

(8,148)

 

(268,506)

籌資活動提供的淨現金

 

(47,111)

 

501,176

匯率變動對現金的影響

 

(179)

(44)

現金、現金等價物和受限制現金的淨增加額

 

47,820

 

114,704

期初現金、現金等價物及限制性現金餘額

 

144,531

156,333

期末現金、現金等價物及限制性現金餘額

$

192,351

$

271,037

非現金投資和融資活動:

BAQSIMI的递延付款® acquisition

$

$

121,699

包括應付帳款的資本支出

$

5,120

$

4,496

以營業租賃之租賃權作為交換之營業租賃負債

$

2,386

$

9,890

增補現金流量資訊:

支付的利息,抵銷資本化的利息

$

22,389

$

12,098

所得稅已支付金額

$

29,000

$

2,136

請參閱附表的簡明綜合基本報表附註

-5-

目錄

amphastar pharmaceuticals, INC.

基本報表附註

(未經查核)

備註1。 一般事項。

Amphastar Pharmaceuticals, Inc.,一家德州公司(以下簡稱「公司」)是一家專注於開發、製造、銷售技術挑戰性的仿製和專有注射、吸入和鼻腔產品的生物製藥公司。其中包括具有很高技術壁壘的產品。此外,該公司還銷售胰島素原料藥品(API)產品。公司的大多數產品用於醫院或急診臨床環境,主要通過集團採購組織和藥品批發商進行合約採購和分銷。公司的胰島素API產品銷售給其他製藥公司,供其自家產品使用,同時也由公司用於開發注射成品藥品。公司的吸入產品Primatene MIST,®主要通過藥品零售商分銷。

請閱讀隨附的未經審核簡明合併基本報表,以及2023年12月31日年度已提交給證券交易委員會(SEC)的公司綜合業務報告Form 10-k的經已審核的合併基本報表及相關附註。相應簡明合併基本報表未包含或簡化了正常收錄在依據美國公認會計原則(GAAP)編製的年度財務報表中的某些信息及腳註。年終簡明合併資產負債表係從經審核的財務報表衍生出來。隨附的中期未經審核的財務報表中反映出所有管理層認為必需進行的為了公允呈現公司綜合財務狀況、營業結果、綜合收益、股東權益和現金流量所必需的調整。除非另有說明,所有此類調整屬正常、週期性。公司中期營業結果、綜合收益和現金流量不一定反映出公司未來期間可能實現的營業結果和現金流量。

附註2。 重要會計政策摘要

報告基礎

未經審核的簡明綜合財務報表包括公司及其子公司的帳戶,並按照GAAP準備。 在準備簡明綜合財務報表時,所有公司內部活動均已予以消除。 據管理層意見,附隨的未經審核的簡明綜合財務報表包括所有調整,這些調整屬於正常循環性質,並且需要合理呈現公司的綜合財務狀況,營運結果和現金流量。

公司的子公司包括:(1) International Medication Systems, Limited,縮寫為IMS;(2) Armstrong Pharmaceuticals, Inc.,縮寫為Armstrong;(3) Amphastar Nanjing Pharmaceuticals Inc.,縮寫為ANP;(4) Amphastar France Pharmaceuticals, S.A.S.,縮寫為AFP;(5) Amphastar Uk Ltd.,縮寫為AUk;(6) International Medication Systems (UK) Limited,縮寫為IMS Uk;和(7) Amphastar Medication Co., LLC,縮寫為Amphastar Medication。

對未合併聯營公司的投資

當公司在投資者身上具有重大影響力,但對被投資者沒有控股權時,公司採用權益法會計。這些投資所得的收益或虧損按公司在附表中的營運簡明合併報表報告為「未合併聯營公司權益中的虧損」。使用權益法核算的投資,如果被投資者的財務報表未能及時提供給投資者在當前報告日期應用權益法,則可以滯後報告長達三個月。

-6-

目錄

amphastar pharmaceuticals, INC.

基本報表附註

(未經查核)

權益法投資的攜帶金額在附帶的簡明合併資產負債表中報告為「對非合併聯營的投資」。公司的權益法投資按成本報告,每個期間調整為公司投資者的收益或損失和支付的分紅派息,如果有的話。

估計的使用

根據GAAP製備的縮短的合並基本報表要求管理層進行估計和假設,從而影響縮短的合並基本報表和隨附註的金額報告。實際結果可能會與這些估計有所不同。主要的會計估計包括:收購資產的公允價值,金融工具的公允價值,折扣準備金,退款和回扣準備金,產品退貨準備金,庫存調整為淨實現價值,投資損耗,長期和無形資產及商譽,訴訟準備金,基於股份報酬費用的股價波動性,推遲稅負資產的評價備抵,以及不確定所得稅位置的負債。

外國貨幣

公司、其國內子公司、其中國子公司ANP和其英國子公司AUk的功能貨幣為美元,或USD。ANP將其記錄簿記在人民幣中。這些記錄會根據當前或歷史匯率折合為美元的功能貨幣。由此產生的貨幣折合調整和其他交易性外幣兌換匯盈虧將反映在公司的縮短的合並損益表中。

The Company’s French subsidiary, AFP, maintains its books of record in euros. AUK’s subsidiary, IMS Uk, maintains its books of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss).

The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $1.4 2 024年第三季和前九個月,分別報告了1,000萬美元的增益和1,000萬美元的增益。0.4 million gain for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2023, the unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature were a $0.9 百萬虧損和一筆$0.4 million loss, respectively.

綜合收益

公司的綜合收益包括外幣兌換的盈利和損失,以及來自股權法下投資的其他綜合收益的份額。

收購s

公司評估收購和其他類似交易,以判斷該交易應該作為企業合併還是資產收購來核算,首先應用篩選測試來確定所收購的全部淨資產的公允價值是否集中在一個可識別的單一資產或類似可識別資產的群組中。如果符合篩選條件,則將該交易視為資產收購。如果不符合篩選條件,則需要進一步判定公司是否已收購具備創建輸出能力的輸入和實質性過程,這樣才符合企業定義。

-7-

目錄

amphastar pharmaceuticals, INC.

基本報表附註

(未經查核)

符合業務組合定義的併購需使用會計併購方法進行核算,該方法要求將購買價格分配給各自公允價值的取得資產。在業務組合中,若購買價格超出取得資產預估公允價值,則被記錄為商譽。

對於資產收購,使用成本積累模型來確定資產收購的成本。直接交易成本被視為資產收購成本的一部分。資產收購的成本,包括交易成本,根據相對公平值基礎分配給已獲得的可識別資產和承擔的負債,除了非符合條件的資產。在資產收購中不承認商譽。當作為資產收購的交易包含進程研究和開發,或者IPR&D資產時,只有在具有替代未來用途而不僅僅用於特定研究和開發項目時,才能對IPR&D資產進行資本化。資產收購可能包括涵蓋對未來支付義務的條件考慮安排,這些支付對賣家而言取決於未來財務目標的實現。條件考慮,包括承擔的條件考慮,在所有條件都解決且考慮金額已支付或變為應支付之前(除非條件考慮符合衍生品的定義,在這種情況下該金額成為所收購資產的基礎的一部分),在這一點上,該金額根據其資產收購日的相對公平值分配給獲得資產,除了非符合條件的資產。

在確定長壽命資產有用壽命的估計中使用判斷。有用壽命估計是基於預期未來淨現金流量的估計,評估每項資產生命周期,以及競爭趨勢對每項資產生命周期和其他因素的影響等因素。這些判斷可能會對用於將購買考慮金額分配給已獲得的資產和承擔的負債的估計,以及對於或認可的現在和未來運營結果的計時和金額產生重大影響。出於這些原因等,實際結果可能會與估計結果顯著不同。

预资金认购权证发行价为每股9.185美元,不具实质性且高度可预期,因此在基本和摊薄普通股每股净损失的计算中包含预资金认购权证。

主要與Primatene MIST相關的廣告費用已在發生時記錄。®除了與重大商業或媒體活動開發有關的費用,這些費用則在首次展示相應商業活動或媒體活動的期間予以支出,並納入公司簡明綜合營運報表中的銷售、分銷和行銷組件。截至2024年9月30日三個月和九個月結束時,廣告費用分別為$2.5 百萬美元和7.8 百萬。截至2023年9月30日三個月和九個月結束時,廣告費用分別為$1.9 百萬美元和8.1 百萬。

金融工具

公司附屬的簡明綜合資產負債表包括以下金融工具:現金及現金等價物、受限現金、應收賬款、應付賬款、應計費用、短期借款和長期負債。由於這些項目的短期性,公司認為簡明綜合資產負債表中流動資產和負債的帳面金額近似該等金融工具的公平價值。公司的長期負債的帳面價值(參見附註14中可轉換債務)近似於其公平價值,因為所載借款利率與目前為類似到期日的工具提供給公司的利率相當。根據公開的市場交易所報價和其他方法,投資和短期投資以公平價值記錄(見附註9)。公司有時會進入利率互換合約,以管理其對利率變動的風險和長期債務的整體成本。公司的利率互換合約將可變利率換成固定利率。

-8-

目錄

amphastar pharmaceuticals, INC.

基本報表附註

(未經查核)

現金及現金等價物

現金及現金等價物包括現金、貨幣市場帳戶、存款證明和具有三個月或更短原始到期日的高流動性投資。

投資

截至2024年9月30日和2023年12月31日,投資包括存款證明和具有三個至十五個月原始到期日的投資級別企業、機構和市政債券。

限制現金

限制性現金是公司為了保證其在法國支付給某些供應商的款項所需要提供的抵押品。截至2024年9月30日和2023年12月31日,限制性現金餘額為$0.2 百萬美元之間。

受限短期投資

受限短期投資包括作為擔保函授信的存款證明,以符合工傷保險自我保險的要求。這些存款證明的原始到期期限超過三個月,但不超過一年。截至2024年9月30日和2023年12月31日,受限短期投資餘額為$2.2 百萬美元之間。

递延所得税

公司採用負債法會計方法處理所得稅,根據會計基礎和資產負債表之間的暫時性差異,使用通過的稅率判斷遞延稅金。當推斷遞延所得稅資產不會實現的可能性大於實現時,會記錄一筆評價準備。

債務發行成本

與非輪借債務相關的債務發行成本將被認定為相關債務餘額的減少,並按照有效利率法削減至相關債務的合同期限內的利息費用。與循環借款相關的債務發行成本將資本化到簡明合併資產負債表的其他長期資產中,並按相關循環債務的期限分期攤銷至利息費用。

可轉換債券

公司將其可轉換債務工具視為單一計量單位,作為負債,因為公司判斷轉換條款不需要根據《會計標準統一編碼》或ASC 815-15進行作為衍生金融工具的細分。 衍生品和避險 而且公司沒有以實質溢價發行其可轉換債務工具。公司將債務發行成本記錄為其簡明綜合資產負債表上的相對負債,並根據可轉換債務工具的合約期間使用有效利率攤銷。

根據會計準則更新,或ASU,2020-06, 債務─具轉換權及其他選擇權(子題470-20)以及衍生工具和避險實體內之合約股權(主題815-40):對實體中的可轉換工具和合同進行會計處理自有權益,公司評估可轉換債務工具,以判斷轉換功能是獨立存在還是內嵌。如果轉換功能是內嵌的,

-9-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

feature is not bifurcated from the host instrument. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20, “Debt with Conversion and Other Options” for consideration of any beneficial conversion features. If no beneficial conversion features exist that require separate recognition, convertible debt instruments are accounted for as a single liability measured at its amortized cost as long as no other features require separation and recognition as derivatives.

Litigation, Commitments and Contingencies

Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized.

Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the disclosure requirements related to the new standard.

In December 2023, the FASB issued Accounting Standard Update 2023-09, Income taxes (Topic 740): Improvements to Income Tax Disclosures which requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the disclosure requirements related to the new standard.

Note 3. BAQSIMI® Asset Acquisition

On June 30, 2023, the Company completed its acquisition of BAQSIMI® glucagon nasal powder, or BAQSIMI®, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated April 21, 2023.

The Company accounted for the BAQSIMI® acquisition as an asset acquisition in accordance with ASC 805, Business Combinations, as substantially all the fair value of the assets acquired was concentrated in a single identifiable asset, BAQSIMI® product rights. The BAQSIMI® product rights include the license for the BAQSIMI® intellectual property, regulatory documentation, marketing authorizations, and domain names, which are considered a single asset as they are inextricably linked.

-10-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The total purchase price was allocated to the acquired assets based on their relative fair values, as follows:

Fair Value

(in thousands)

Property, plant, and equipment

    

$

34,426

BAQSIMI® product rights

 

591,338

Deferred tax assets

2,341

Total assets acquired

$

628,105

The Company amortizes the acquired intangible asset to cost of revenues on a straight line basis over its estimated useful life of 24 years (see Note 10 for additional information).

A portion of the consideration for the asset acquisition was a deferred cash payment. The fair value of the deferred cash payment was accreted to its full $129.0 million amount over a one-year period from the date of acquisition through interest expense. During the nine months ended September 30, 2024, the Company recognized $3.6 million of interest expense related to accretion of the deferred cash payment. During the three and nine months ended September 30, 2023, $1.8 million of interest expense was recognized related to the accretion of the deferred cash payment. The Company made the $129.0 million deferred cash payment in June 2024.

The Company may also be required to pay additional contingent consideration of up to an aggregate of $575.0 million in cash as part of the BAQSIMI® acquisition, based on the achievement of certain net sales milestones. Through September 30, 2024, the Company has not triggered any milestones and therefore no amounts have been recognized or paid.

Manufacturing Services Agreement

In connection with the closing of the acquisition, the Company entered into a Manufacturing Services Agreement, or the MSA, with Lilly, pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain manufacturing, packaging, labeling and supply services for BAQSIMI® directly or through third-party contractors to the Company in connection with its operation of the development, manufacture, and commercialization of BAQSIMI®. Upon termination of the MSA, the Company will be obligated to purchase all API, components, and finished goods on hand at prices agreed upon in the MSA.

Transition Services Agreement

In connection with the closing of the acquisition, the Company also entered into a Transition Services Agreement, or the TSA, with Lilly pursuant to which Lilly has agreed, for a period of time not to exceed 18 months, to provide certain services to the Company to support the transition of BAQSIMI® operations to the Company, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities.

Throughout 2024, the Company assumed distribution responsibilities, from Lilly, to its customers in the United States, and certain other countries. As a result, the Company has recorded the sales and related cost of BAQSIMI® in these countries as product revenue, net and cost of revenues, respectively. The Company will continue to assume distribution of BAQSIMI® for the remaining territories on a country by country basis throughout 2024.

-11-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 4. Revenue Recognition

Product revenues, net

In accordance with ASC 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Company’s customers obtain control of the promised goods.

Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements.

The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration including provision for chargebacks and rebates, accrual for product returns, prompt pay discounts, distributor fees, patient co-pay assistance, and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Payment terms offered to customers generally range from 30 to 75 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If the Company expects, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, the amount of consideration is not adjusted for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities rather than a separate performance obligation and are recorded within selling, distribution and marketing expenses in the accompanying condensed consolidated statements of operations.

Provision for Chargebacks and Rebates: The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historical chargeback and rebate rates, and current contract pricing.

The provision for chargebacks and rebates is reflected as a component of product revenues, net. The following table is an analysis of the chargeback and rebate provision:

Nine Months Ended

September 30, 

2024

2023

(in thousands)

Beginning balance

    

$

27,920

    

$

26,606

Provision for chargebacks and rebates

 

218,312

 

200,317

Credits and payments issued to third parties

 

(181,216)

 

(201,650)

Ending balance

$

65,016

$

25,273

Changes in the chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers’ customer mix. Changes in the rebate provision from period to period are primarily dependent on retailers’ and other indirect customers’ purchases. The approach that the Company uses to estimate chargebacks and rebates has been consistently applied for all periods

-12-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 20 days to 60 days after the sale to wholesalers. Accounts receivable and/or accounts payable and accrued liabilities are reduced and/or increased by the chargebacks and rebate amounts depending on whether the Company has the right to offset with the customer.

The provision for chargebacks and rebates is included in the following balance sheet accounts:

September 30, 

December 31, 

2024

2023

(in thousands)

Reduction to accounts receivable, net

$

21,355

    

$

21,861

Accounts payable and accrued liabilities

 

43,661

 

6,059

Total

$

65,016

$

27,920

Accrual for Product Returns: The Company offers certain customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and new competition.

Prompt Pay Discounts: The Company provides its customers with a percentage discount on their invoice if the customers pay within the agreed upon timeframe. The Company expects that its customers will earn prompt pay discounts. The Company estimates the probability of customers paying promptly based on the percentage of discount outlined in the purchase agreement between the two parties, and deducts the full amount of these discounts from gross product sales and accounts receivable at the time revenue is recognized.

Distributor Fees: The Company engages with wholesalers to distribute its products to end customers. The Company pays the wholesalers a fee for services such as: inventory management, chargeback administration, and service level commitments. The Company estimates the amount of distribution services fees to be paid and adjusts the transaction price with the amount of such estimate at the time of sale to the customer. An accrued liability is recorded for unpaid distribution service fees.

Patient Co-Pay Assistance: Co-pay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The accrual for co-pay is based on an estimate of claims and the cost per claim that the Company expects to receive associated with inventory that exists in the distribution channel at period end.

Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers. The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit.

Service revenues derived from research and development contracts are recognized over time based on progress toward satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation. For the three and

-13-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

nine months ended September 30, 2024, revenues from research and development services were $0.1 million and $2.0 million, respectively. For the three and nine months ended September 30, 2023, revenues from research and development services were $0.8 million and $2.1 million, respectively.

Other revenues

Revenues related to sales of BAQSIMI®, which was supplied and sold by Lilly under the TSA during the three and nine months ended September 30, 2024 and 2023, or BAQSIMI® NEB, were recorded on a net basis, similar to a royalty arrangement. This includes revenues in the United States and certain other countries for a portion of the period.

Note 5. Net Income per Share

Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potentially dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP, and potential shares of common stock issuable upon conversion of Convertible Notes of the Company, due March 2029, or the 2029 Convertible Notes.

For the three and nine months ended September 30, 2024, options to purchase 619,847 shares of stock with a weighted-average exercise price of $46.63 per share, were excluded in the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.

For the three months ended September 30, 2023, none of the Company’s options were excluded from the computation of diluted net income per share. For the nine months ended September 30, 2023, options to purchase 45,934 shares of stock with a weighted-average exercise price of $46.01 per share, were excluded from the computation of diluted net income per share because their effect would be anti-dilutive. The 2029 Convertible Notes had no impact on the computation of diluted net income per share as the average stock price during the period was less than the conversion price.

The following table provides the calculation of basic and diluted net income per share for each of the periods presented:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

    

    

    

    

 

Net income

$

40,429

$

49,222

$

121,555

$

101,378

Denominator:

Weighted-average shares outstanding — basic

 

48,621

48,701

48,580

48,368

Net effect of dilutive securities:

Incremental shares from equity awards

 

3,241

5,220

3,727

4,629

Weighted-average shares outstanding — diluted

 

51,862

 

53,921

 

52,307

 

52,997

Net income per share — basic

$

0.83

$

1.01

$

2.50

$

2.10

Net income per share — diluted

$

0.78

$

0.91

$

2.32

$

1.91

-14-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6. Segment Reporting

The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:

Finished pharmaceutical products
APIs

The finished pharmaceutical products segment manufactures, markets and distributes BAQSIMI®, Primatene MIST®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing and contract research revenues. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.

Other revenues includes the portion of BAQSIMI® sales by Lilly on the Company’s behalf under the TSA and is accounted for as a component of the finished pharmaceutical product segment.

Selected financial information by reporting segment is presented below:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Net revenues:

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

189,752

$

176,366

$

538,755

$

455,242

API

 

1,462

4,190

6,689

11,048

Total net revenues

 

191,214

 

180,556

 

545,444

 

466,290

Gross profit (loss):

Finished pharmaceutical products

 

105,544

 

109,499

 

302,322

 

262,742

API

 

(3,603)

(1,096)

(15,115)

(7,761)

Total gross profit

 

101,941

 

108,403

 

287,207

 

254,981

Operating expenses

 

44,893

 

35,725

 

126,932

 

111,974

Income from operations

 

57,048

 

72,678

 

160,275

 

143,007

Non-operating (expenses) income

 

(9,365)

 

(9,041)

 

(14,473)

 

(12,993)

Income before income taxes

$

47,683

$

63,637

$

145,802

$

130,014

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

-15-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The amount of net revenues in the finished pharmaceutical product segment is presented below:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Finished pharmaceutical products segment net revenues:

    

    

    

    

    

    

 

BAQSIMI®

$

40,409

$

$

85,106

$

Glucagon

26,792

29,514

82,700

82,486

Epinephrine

21,341

20,199

75,392

57,004

Primatene MIST®

26,055

24,834

73,077

64,837

Lidocaine

15,884

15,522

41,457

43,174

Phytonadione

11,721

7,449

31,998

33,017

Enoxaparin

 

5,615

 

7,702

 

17,984

25,441

Naloxone

4,037

4,715

12,124

14,774

Other finished pharmaceutical products

 

35,503

 

37,730

 

99,309

 

105,808

Total finished pharmaceutical products net revenues

187,357

147,665

519,147

426,541

BAQSIMI® NEB

2,395

28,701

19,608

28,701

Total finished pharmaceutical products segment net revenues

$

189,752

$

176,366

$

538,755

$

455,242

The amount of depreciation and amortization expense included in cost of revenues by reporting segment is presented below:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

(in thousands)

Depreciation and amortization expense

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

8,755

$

8,616

$

26,086

$

13,143

API

 

1,038

 

1,003

 

3,045

2,938

Total depreciation and amortization expense

$

9,793

$

9,619

$

29,131

$

16,081

Net revenues and carrying values of long-lived assets, which includes property, plant and equipment, as well as finance and operating lease right-of-use assets, by geographic regions, based on where the Company conducts its operations are as follows:

Net Revenues

Long-Lived Assets

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

September 30, 

December 31, 

2024

2023

2024

2023

2024

2023

(in thousands)

United States(1)

    

$

186,514

    

$

178,056

    

$

532,591

    

$

459,909

    

$

187,410

    

$

186,083

China

 

178

833

2,145

2,142

 

103,009

 

91,913

France

 

4,522

1,667

10,708

4,239

 

37,099

 

37,647

Total

$

191,214

$

180,556

$

545,444

$

466,290

$

327,518

$

315,643

(1) Includes Other revenues from the sales of BAQSIMI®.

-16-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 7. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, Cencora Inc., formally AmerisourceBergen, or Cencora, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Lilly currently manufactures and sells BAQSIMI® on the Company’s behalf pursuant to the terms of the TSA in certain jurisdictions (see Note 3 for additional information). The Company considers these four customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three and nine months ended September 30, 2024 and 2023, and accounts receivable as of September 30, 2024 and December 31, 2023, respectively. The following table provides accounts receivable and net revenue information for these major customers:

% of Total Accounts

% of Net

Receivable

Revenues

Three Months Ended

Nine Months Ended

 

September 30, 

December 31, 

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

    

2024

 

2023

 

McKesson

 

29

%

26

%

26

%

22

%

25

%

25

%

Cencora

 

28

%

16

%

21

%

17

%

20

%

20

%

Cardinal Health

 

17

%

13

%

20

%

15

%

20

%

16

%

Lilly

2

%

20

%

1

%

16

%

4

%

6

%

Supplier Concentrations

The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Note 8. Fair Value Measurements

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:

Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;

Level 2 – Inputs to measure fair value are based on the following: (a) quoted prices in active markets on similar assets or liabilities, (b) quoted prices for identical or similar instruments in inactive markets, or (c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and

Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.

-17-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

As of September 30, 2024 and December 31, 2023, cash equivalents include money market accounts and corporate and municipal bonds with original maturities of less than three months. Investments consist of certificates of deposit as well as investment-grade corporate, agency and municipal bonds with original maturity dates between three and fifteen months. The certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheets, which approximates their fair value determined based on Level 2 inputs. The corporate, agency and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses. The fair value of such bonds is disclosed in Note 9 and was determined based on Level 2 inputs. The restrictions on restricted cash and investments have an immaterial effect on the fair value of these financial assets.

The fair values of the Company’s financial assets and liabilities measured on a recurring basis as of September 30, 2024 and December 31, 2023, are as follows:

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

(in thousands)

 

Cash equivalents

$

143,637

$

143,637

$

$

Restricted cash

235

235

Short-term investments

26,322

26,322

Restricted short-term investments

 

2,200

 

 

2,200

 

Interest rate swaps related to variable rate loans

(6,881)

(6,881)

Total assets and liabilities measured at fair value as of September 30, 2024

$

165,513

$

143,872

$

21,641

$

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

(in thousands)

Cash equivalents

$

116,441

$

116,441

$

$

Restricted cash

235

235

Short-term investments

37,142

37,142

Restricted short-term investments

 

2,200

 

 

2,200

 

Interest rate swaps related to variable rate loans

(5,243)

(5,243)

Total assets and liabilities measured at fair value as of December 31, 2023

$

150,775

$

116,676

$

34,099

$

The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.

Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include investments in unconsolidated affiliates, long-lived assets, goodwill, and intangible assets for which the fair value is determined as part of an impairment test. As of September 30, 2024, and December 31, 2023, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

The Company’s deferred compensation plan assets are valued using the cash surrender value of the life insurance policies and are not included in the table above.

-18-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 9. Investments

The following is a summary of the Company’s investments that are classified as held-to-maturity:

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

Corporate and agency bonds (due within 1 year)

$

31,903

$

67

$

(2)

$

31,968

Total investments as of September 30, 2024

$

31,903

$

67

$

(2)

$

31,968

Corporate and agency bonds (due within 1 year)

$

73,815

$

7

$

(21)

$

73,801

Corporate and agency bonds (due within 1 to 3 years)

14,621

56

(1)

14,676

Municipal bonds (due within 1 year)

1,081

1

1,082

Total investments as of December 31, 2023

$

89,517

$

64

$

(22)

$

89,559

At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, identifying neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.

The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company’s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements.

Note 10. Goodwill and Intangible Assets

The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

BAQSIMI® product rights(1)

24

$

591,338

$

30,799

$

560,539

Patents

 

15

 

193

92

 

101

Land-use rights

 

39

 

2,540

865

 

1,675

Subtotal

 

24

 

594,071

 

31,756

 

562,315

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,256

 

 

3,256

Subtotal

 

*

 

32,481

 

 

32,481

As of September 30, 2024

 

*

$

626,552

$

31,756

$

594,796

-19-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

BAQSIMI® product rights(1)

24

$

591,338

$

12,319

$

579,019

Patents

 

12

 

486

376

 

110

Land-use rights

 

39

 

2,540

815

 

1,725

Subtotal

 

24

 

594,364

 

13,510

 

580,854

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,216

 

 

3,216

Subtotal

 

*

 

32,441

 

 

32,441

As of December 31, 2023

 

*

$

626,805

$

13,510

$

613,295

* Intangible assets with indefinite lives have an indeterminable average life.

(1)

See Note 3.

Goodwill

The changes in the carrying amounts of goodwill are as follows:

September 30, 

December 31, 

 

2024

2023

 

(in thousands)

 

Beginning balance

    

$

3,216

    

$

3,126

Currency translation

 

40

 

90

Ending balance

$

3,256

$

3,216

Note 11. Inventories

Inventories consist of the following:

September 30, 

December 31, 

 

2024

2023

 

(in thousands)

 

Raw materials and supplies

    

$

60,536

    

$

50,082

Work in process

 

36,016

 

30,822

Finished goods

 

33,764

 

24,929

Total inventories

$

130,316

$

105,833

Charges of $0.9 million and $10.1 million were included in the cost of revenues in the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2024, respectively, to adjust the Company’s inventory and related firm purchase commitments to its net realizable value. For the three months ended September 30, 2023, the Company had an immaterial amount that was included in cost of revenues to adjust the Company’s inventory and related firm purchase commitments to its net realizable value. For the nine months ended September 30, 2023, charges of $9.6 million were included in the cost of revenues to adjust the Company’s inventory and related firm purchase commitments to its net realizable value.

-20-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 12. Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

September 30, 

December 31, 

 

2024

2023

 

(in thousands)

 

Buildings

    

$

170,203

    

$

168,771

Leasehold improvements

 

42,012

 

41,686

Land

 

7,499

 

7,484

Machinery and equipment

 

278,200

 

259,484

Furniture, fixtures, and automobiles

 

34,795

 

31,943

Construction in progress

 

28,864

 

18,676

Total property, plant, and equipment

 

561,573

 

528,044

Less accumulated depreciation

 

(266,189)

 

(245,298)

Total property, plant, and equipment, net

$

295,384

$

282,746

Note 13. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

September 30, 

December 31, 

2024

2023

(in thousands)

Accrued customer fees and rebates

$

59,949

$

16,702

Accrued payroll and related benefits

29,207

25,203

Accrued product returns, current portion

13,480

12,263

Accrued loss on firm purchase commitments

812

918

Other accrued liabilities

15,732

12,842

Total accrued liabilities

 

119,180

 

67,928

Accounts payable

 

34,088

 

25,438

Total accounts payable and accrued liabilities

$

153,268

$

93,366

-21-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 14. Debt

Debt consists of the following:

September 30, 

December 31, 

2024

2023

(in thousands)

Convertible Debt

2029 Convertible Notes

$

345,000

$

345,000

Term Loan

Wells Fargo Term Loan due June 2028

250,000

250,000

Mortgage Loans

Mortgage payable with East West Bank paid off June 2024

8,016

Other Loans and Payment Obligations

French government loans due December 2026

168

158

Line of Credit Facilities

    

    

    

Line of credit facility with China Merchant Bank due October 2026

Wells Fargo Revolving line of credit facility due June 2028

Line of credit facility with ICBC Bank due November 2033

13,565

Equipment under Finance Leases

 

485

 

616

Total debt

 

609,218

 

603,790

Less current portion of long-term debt

 

252

 

436

Less: Loan issuance costs

12,520

13,775

Long-term debt, net of current portion and unamortized debt issuance costs

$

596,446

$

589,579

Credit Agreement

2029 Convertible Notes

In September 2023, the Company issued the 2029 Convertible Notes, in the aggregate principal amount of $345.0 million in a private offering pursuant to Section 4(a)(2) and Rule 144A under the Securities Act of 1933, as amended. The Company used portions of the net proceeds from the 2029 Convertible Notes to (i) repay approximately $200.0 million of the Company’s borrowings under the Wells Fargo Term Loan and (ii) repurchase $50.0 million of the Company’s common stock.

In connection with the issuance of the 2029 Convertible Notes, the Company incurred approximately $10.8 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees. Unamortized debt issuance costs related to the 2029 Convertible Notes were $8.8 million as of September 30, 2024. The fair value of the 2029 Convertible Notes was approximately $365.4 million as of September 30, 2024 based on level 2 inputs.

The 2029 Convertible Notes are general senior, unsecured obligations and bear an interest rate of 2.0% per year. The

-22-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2029 Convertible Notes were issued pursuant to an indenture, dated September 15, 2023, or the Indenture, between the Company and U.S. Bank Trust Company, National Association, as trustee.

The 2029 Convertible Notes will rank senior in right of payment to all of the Company’s indebtedness that is expressly subordinated in right of payment to the 2029 Convertible Notes; equal in right of payment to all of the Company’s unsecured indebtedness that is not so subordinated; effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, including any amount outstanding under the Company’s credit facilities; and structurally junior to all indebtedness and other liabilities of the Company’s current or future subsidiaries, including trade payables.

Interest is payable semi-annually in arrears on March 15 and September 15 of each year. The 2029 Convertible Notes may bear additional interest under specified circumstances relating to the Company’s failure to comply with its reporting obligations under the Indenture or if the 2029 Convertible Notes are not freely tradeable as required by the Indenture.

The 2029 Convertible Notes will mature on March 15, 2029, unless earlier converted, repurchased or redeemed.

Conversions of the 2029 Convertible Notes will be settled in cash up to the aggregate principal amount of the 2029 Convertible Notes to be converted, and cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election, with respect to the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount.

Holders may convert their 2029 Convertible Notes at their option prior to the close of business on the business day immediately preceding December 15, 2028, in multiples of $1,000 principal amount, only under the following circumstances; (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2029 Convertible Notes on each applicable trading day, (ii) during the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, per $1,000 principal amount of the 2029 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day, (iii) if the Company calls the 2029 Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, and (iv) upon the occurrence of specified corporate events defined in the Indenture.

On or after December 15, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2029 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.

The Company may redeem the 2029 Convertible Notes, at its option, in whole or in part (subject to certain limitations), on or after September 20, 2026 and prior to the 41st scheduled trading day preceding the maturity date, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

The initial conversion rate is 15.8821 shares of the Company’s common stock per $1,000 principal amount of the 2029 Convertible Notes, which represents an initial conversion price of approximately $62.96 per share of common stock. The initial conversion price of $62.96 represents a premium of approximately 35.0% over the last reported sale price of the

-23-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Company’s common stock on Nasdaq Global Select Market on September 12, 2023. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the Indenture.

If a fundamental change, as defined in the Indenture, occurs at any time prior to the maturity date, then, subject to certain conditions, holders of the 2029 Convertible Notes may require the Company to repurchase for cash all or any portion of their 2029 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2029 Convertible Notes to be repurchased, plus any accrued and unpaid interest. In addition, following certain specified corporate events or if the Company issues a notice of redemption, the Company will, under certain circumstances, increase the conversion rate for holders who convert their 2029 Convertible Notes in connection with such corporate event or during a redemption period.

Syndicated Line of Credit Facility with ICBC Bank – Due November 2033

In January 2024, the Company entered into a credit agreement with Industrial and Commercial Bank of China Limited, or ICBC Bank, acting as a lender and as agent for other lenders. The credit agreement allows the Company to borrow up to $40.0 million secured by equipment and buildings at ANP. The interest rate and other terms will be determined at the time of the borrowing, depending on the type of loan requested. The credit agreement expires in November 2033.

As of September 30, 2024, the Company borrowed approximately $13.6 million under the credit agreement. The loan bears interest at the prime rate as published by The People’s Bank of China minus 0.2%. Interest payments are due quarterly and repayment of the principal amount is biannual and begins in May 2026. As of September 30, 2024, the Company had $13.6 million of principal outstanding under this loan, which is recorded net of loan issuance costs of $0.8 million.

Interest Rate Swap Contract

As of September 30, 2024, the fair value of the loans listed above approximated their carrying amount based on Level 2 inputs, with the exception of the 2029 Convertible Notes. For the Wells Fargo Term Loan, the Company has entered into a fixed interest rate swap contract to exchange the variable interest rates for fixed interest rates. The interest rate swap contract is recorded at fair value in the other assets line in the condensed consolidated balance sheets. Changes in the fair values of interest rate swaps were $7.4 million loss and $1.6 million loss for the three and nine months ended September 30, 2024, respectively. Changes in the fair values of interest rate swaps were $4.9 million gain and $2.7 million gain for the three and nine months ended September 30, 2023, respectively.

Covenants

At September 30, 2024 and December 31, 2023, the Company was in compliance with all of its debt covenants.

-24-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 15. Income Taxes

The following table sets forth the Company’s income tax provision for the periods indicated:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

 

    

2024

    

2023

    

2024

    

2023

 

(in thousands)

 

Income before taxes

$

47,683

$

63,637

$

145,802

$

130,014

Income tax provision

7,254

 

14,025

23,674

 

27,160

Income before equity in losses of unconsolidated affiliate

$

40,429

$

49,612

$

122,128

$

102,854

Income tax provision as a percentage of income before income taxes

15.2

%

 

22.0

%

16.2

%

 

20.9

%

Valuation Allowance

In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. Ultimately, realization depends on the existence of future taxable income. Management considers sources of taxable income such as income in prior carryback periods, future reversal of existing deferred taxable temporary differences, tax-planning strategies, and projected future taxable income.

The Company continues to record a full valuation allowance on the net deferred income tax assets of its France subsidiary, AFP, and its U.K. subsidiaries, AUK and IMS UK. The Company will continue to do so until the subsidiaries generate sufficient taxable income to realize their respective deferred income tax assets.

The Company records a valuation allowance on net deferred income tax assets in states where it files separately and will continue to do so until sufficient taxable income is generated to realize these state deferred income tax assets.

Note 16. Stockholders' Equity

Share Buyback Program

Pursuant to the Company’s existing share buyback program, the Company purchased 797,038 and 1,004,326 shares of its common stock, during the three and nine months ended September 30, 2024, for total consideration of $35.0 million and $43.5 million, respectively. The Company purchased 1,072,041 and 1,338,757 shares of its common stock during the three and nine months ended September 30, 2023, for total consideration of $50.0 million and $58.1 million, respectively.

The Company’s Board of Directors authorized a $50.0 million increase to the Company’s share buyback program in June 2024, and an additional $50.0 million increase in November 2024, which is expected to continue for an indefinite period of time. Since the inception of the program, the Company’s Board of Directors has authorized a total of $385.0 million in the share buyback program. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.

Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets.

-25-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Amended and Restated 2015 Equity Incentive Plan

In February 2024, the Board of Directors approved the Company’s amended and restated 2015 Equity Incentive Plan, or the Amended 2015 Plan, which was subsequently approved by the Company’s stockholders, and accordingly, adopted by the Company in June 2024. The Amended 2015 Plan extends the terms of the 2015 Equity Incentive Plan, or the Original 2015 Plan, and makes certain other changes. The term of the Amended 2015 Plan will be extended indefinitely, however, the Company’s ability to grant incentive stock options thereunder will continue through February 2034.

As of September 30, 2024, the Company reserved an aggregate of 7,817,319 shares of common stock for future issuance under the Amended 2015 Plan.

2014 Employee Stock Purchase Plan

As of September 30, 2024, the Company has issued 1,246,323 shares of common stock under the ESPP and 753,677 shares of its common stock remain available for issuance under the ESPP.

In May 2024, the Company issued 54,189 shares at a purchase price of $35.98 per share under the ESPP. For the three and nine months ended September 30, 2024, the Company recorded ESPP expense of $0.2 million and $0.9 million, respectively. For the three and nine months ended September 30, 2023, the Company recorded ESPP expense of $0.2 million and $0.8 million, respectively.

Share-Based Award Activity and Balances

The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. Compensation cost for all share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method over the requisite service period.

The weighted-averages for key assumptions used in determining the fair value of options granted are as follows:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

 

Average volatility

 

%  

40.2

%  

41.3

%

41.4

%

Average risk-free interest rate

 

%  

4.4

%  

4.2

%

4.1

%

Weighted-average expected life in years

 

6.3

6.2

6.2

Dividend yield rate

 

%  

%  

%

%

-26-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

A summary of option activity under all plans for the nine months ended September 30, 2024, is presented below:

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2023

7,762,298

$

19.70

 

    

    

    

Options granted

 

642,985

46.27

Options exercised

 

(1,611,117)

13.66

Options forfeited

 

(21,138)

35.10

Options expired

 

Outstanding as of September 30, 2024

 

6,773,028

$

23.61

5.12

$

168,760

Exercisable as of September 30, 2024

 

4,968,365

19.02

3.97

$

146,600

Vested and expected to vest as of September 30, 2024

6,617,113

23.24

5.04

$

167,346

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at September 30, 2024.

For the three and nine months ended September 30, 2024, the Company recorded expense of $2.7 million and $9.0 million, respectively, related to stock options granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expense of $2.2 million and $7.5 million, respectively, related to stock options granted under all plans.

Information relating to option grants and exercises is as follows:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per share

$

$

21.49

$

21.89

$

16.76

Intrinsic value of options exercised

 

6,218

 

5,628

 

48,381

 

24,544

Cash received from options exercised

 

3,332

 

2,277

 

9,154

 

12,015

Total fair value of the options vested during the period

 

111

 

167

 

9,815

 

8,887

A summary of the status of the Company’s non-vested options as of September 30, 2024, and changes during the nine months ended September 30, 2024, are presented below:

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2023

2,076,355

$

12.68

Options granted

 

642,985

21.89

Options vested

 

(893,539)

10.98

Options forfeited

 

(21,138)

16.19

Non-vested as of September 30, 2024

 

1,804,663

 

16.76

As of September 30 2024, there was $21.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock option based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures.

-27-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Restricted Stock Units

The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to four years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of the underlying common stock. The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period using the straight-line method. For the three and nine months ended September 30, 2024, the Company recorded total expenses of $2.7 million and $8.8 million, respectively, related to RSU awards granted under all plans. For the three and nine months ended September 30, 2023, the Company recorded expenses of $2.2 million and $7.3 million, respectively, related to RSU awards granted under all plans.

As of September 30, 2024, there was $22.6 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSU-based compensation arrangements granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.6 years and will be adjusted for future changes in estimated forfeitures.

Information relating to RSU grants and deliveries is as follows:

Total Fair Market

 

Total RSUs

Value of RSUs

 

    

Issued

    

Issued(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2023

 

920,376

RSUs granted

 

303,788

$

14,060

RSUs forfeited

 

(9,620)

RSUs vested(2)

 

(388,668)

RSUs outstanding at September 30, 2024

 

825,876

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.

Share-based Compensation Expense

The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statement of operations as follows:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

2024

2023

2024

 

2023

 

(in thousands)

 

Cost of revenues

    

$

1,133

    

$

1,004

    

$

4,583

    

$

3,868

Operating expenses:

Selling, distribution, and marketing

 

249

 

213

 

777

 

649

General and administrative

 

3,710

 

2,975

 

11,239

 

9,323

Research and development

 

504

 

452

 

2,137

 

1,780

Total share-based compensation

$

5,596

$

4,644

$

18,736

$

15,620

-28-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 17. Employee Benefits

401(k) Plan

The Company has a defined contribution 401(k) plan, or the Plan, whereby eligible employees voluntarily contribute up to a defined percentage of their annual compensation. The Company matches contributions at a rate of 50% on the first 6% of employee contributions, and pays the administrative costs of the Plan. Total employer contributions for the three and nine months ended September 30, 2024 were approximately $0.6 million and $2.0 million, respectively, compared to the prior year expense of $0.5 million and $1.7 million for the three and nine months ended September 30, 2023, respectively.

Defined Benefit Pension Plan

The Company’s subsidiary, AFP, has an obligation associated with a defined-benefit plan for its eligible employees. This plan provides benefits to the employees from the date of retirement and is based on the employee’s length of time employed by the Company. The calculation is based on a statistical calculation combining a number of factors that include the employee’s age, length of service, and AFP employee turnover rate.

The liability under the plan is based on a discount rate of 3.25% as of September 30, 2024 and December 31, 2023. The liability is included in other long-term liabilities in the accompanying condensed consolidated balance sheets. The plan is currently unfunded, and the benefit obligation under the plan was $2.8 million and $2.6 million at September 30, 2024 and December 31, 2023, respectively. The Company recorded an immaterial amount of expense under the plan for each of the three and nine months ended September 30, 2024 and 2023.

Non-qualified Deferred Compensation Plan

In December 2019, the Company established a non-qualified deferred compensation plan. The plan allows certain eligible participants to defer a portion of their cash compensation and provides a matching contribution at the discretion of the Company. The plan obligations are payable upon retirement, termination of employment and/or certain other times in a lump-sum distribution or in installments, as elected by the participant in accordance with the plan. Participants can allocate their deferred compensation amongst various investment options with earnings accruing to the participant. The Company has established a Rabbi Trust to fund the plan obligations and to hold the plan assets. Eligible participants began contributing to the plan in January 2020. The plan assets were valued at approximately $9.4 million and $6.8 million as of September 30, 2024 and December 31, 2023, respectively. The plan liabilities were valued at approximately $9.8 million and $7.1 million as of September 30, 2024, and December 31, 2023, respectively. The plan assets and liabilities are included in other long-term assets and other long-term liabilities, respectively, on the Company’s condensed consolidated balance sheets.

Note 18. Commitments and Contingencies

Purchase Commitments

As of September 30, 2024, the Company has entered into commitments to purchase equipment and raw materials for an aggregate amount of approximately $95.9 million.

Note 19. Related Party Transactions

Investment in Hanxin Pharmaceutical Technology, Co., Ltd.

The Company has an 11.5% ownership in Hanxin Pharmaceutical Technology Co., Ltd, or Hanxin, that is accounted for as an equity method investment. The Company maintains a seat on Hanxin’s board of directors, and Henry Zhang, the

-29-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

son of Dr. Jack Zhang, is an equity holder, the general manager, and the chairman of the board of directors of Hanxin. Additionally, Dr. Mary Luo and Dr. Jack Zhang, have an ownership interest in Hanxin through an affiliated entity. As a result, Hanxin is a related party.

Contract manufacturing agreement with Hanxin

The Company, has various contract manufacturing agreements with Hanxin and its subsidiaries, whereby Hanxin will develop several active pharmaceutical ingredients and finished products for the Chinese market and will engage the Company to manufacture the products on a cost-plus basis.

During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.5 million, respectively, of revenue from manufacturing services provided to Hanxin. During the three and nine months ended September 30, 2023, the Company recognized an immaterial amount of revenue from manufacturing services provided to Hanxin. As of September 30, 2024, the Company had $0.4 million of receivables from Hanxin.

Contract Research Agreement with Hanxin

In July 2022, the Company entered into a three-year contract research agreement with Hanxin, a related party, whereby Hanxin will develop Recombinant Human Insulin Research Cell Banks, or RCBs, for the Company and license the RCBs to the Company subject to a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license. Hanxin will also perform scale-up manufacturing process development using the RCBs for the Company.

During the three months ended September 30, 2024, the Company did not have any payments under the amended agreement and during the nine months ended September 30 2024, the Company paid $0.2 million under the amended agreement. During the three and nine months ended September 30, 2023, the Company paid $0.4 million and $1.0 million, respectively, under the amended agreement. As of September 30, 2024, the Company had an immaterial amount payable to Hanxin.

Supply Agreement with Letop

In November 2022, the Company, entered into a supply agreement with Nanjing Letop Biotechnology Co., Ltd., or Letop, which is considered a related-party due to an ownership stake of Henry Zhang. Under the terms of the supply agreement Letop will manufacture and deliver chemical intermediates to the Company on a cost-plus basis. The agreement is effective for three years and the total cost of the agreement shall not exceed $1.5 million, with payments adjusted based on the then current exchange rates.

During the three and nine months ended September 30, 2024, the Company paid an immaterial amount under this agreement. During the three months ended September 30, 2023, the Company did not have any payments under this agreement. During the nine months ended September 30, 2023, the Company paid $0.7 million, under this agreement. As of September 30, 2024, the Company did not have any amounts payable to Letop.

Primatene MIST® Distribution agreement with Hong Kong Genreach Limited

In August 2024, the Company entered into a distribution agreement with Hong Kong Genreach Limited, or Genreach, a wholly owned subsidiary of Hanxin, a related party. Per the terms of the agreement, the Company has appointed Genrearch as the exclusive distributor to market and sell Primatene MIST® in Mainland China, Taiwan, Hong Kong, and Macau in the Greater China region. Genreach will be responsible for obtaining any and all regulatory approvals in the region for Primatene MIST®.

The term of the agreement is ten years, with both parties having termination rights without cause after the completion of the second contract year.

-30-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 20. Litigation

Employment Litigation

On April 15, 2024, a former employee (“Plaintiff”) initiated an employment litigation against Amphastar and IMS by filing a complaint, as amended, having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the class action complaint.

On June 20, 2024, a former employee (“Plaintiff”) initiated an employment litigation against Amphastar, IMS and Roth Staffing Companies L.P. by filing a complaint having individual and class action claims for alleged violations of the California Labor Code pertaining to wage and hour, and other state laws. This complaint was filed in the Superior Court of California for the County of Los Angeles. In the complaint, the Plaintiff is seeking damages and related remedies under California Law, as well as various penalty payments under the California Labor Code. The Company intends to vigorously defend itself against the complaint.

Albuterol sulfate Inhalation Aerosol Patent Litigation

On July 25, 2024, Teva Branded Pharmaceutical Products R&D, Inc. (“Teva Branded”), Norton (Waterford) Ltd. (“Norton”), and Teva Pharmaceuticals USA, Inc. (“Teva USA”), collectively referred to as (“Plaintiff”) filed a Complaint in the United States District Court for the District of Delaware (“Delaware Court”) against the Company for infringement of U.S. Patent No. 9,463,289, with regard to Amphastar’s ANDA No. 212447, for approval to manufacture and sell generic version of ProAir® HFA (albuterol sulfate) Inhalation Aerosol. On October 21, 2024, Plaintiff amended its complaint against the Company to include additional claims for infringement of U.S. Patent No. 9,808,587 and 10,561,808, with regard to Amphastar’s ANDA No. 212447, for approval to manufacture and sell generic version of ProAir® HFA (albuterol sulfate) Inhalation Aerosol. The Company intends to vigorously defend this patent lawsuit.

Other litigation

The Company is subject to various claims, arbitrations, investigations, and lawsuits from time to time arising in the ordinary course of business. In addition, third parties may, from time to time, assert claims against the Company in the forms of letters and other communications. Currently, the Company is subject to a lawsuit for a property and casualty claim, for which it has recorded an estimated liability of $6.0 million within accounts payable and other accrued liabilities on the condensed balance sheet as of September 30, 2024. This estimated liability is fully covered by the Company’s insurance policies. The $6.0 million insurance recovery related to this claim is recorded within prepaid expenses and other current assets on the condensed consolidated balance sheet as of September 30, 2024.

The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In the opinion of management, the ultimate resolution of any such matters is not expected to have a material adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable and the Company’s view of these matters may change in the future. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

-31-

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the “Condensed Consolidated Financial Statements” and the related notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report. This discussion contains forward-looking statements that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the “Special Note About Forward-Looking Statements,” above and described in greater detail elsewhere in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2023, particularly in Item 1A. “Risk Factors”.

Overview

We are a bio-pharmaceutical company focusing primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. We currently manufacture and sell over 25 products.

Our largest products by net revenues currently include BAQSIMI®, Primatene MIST®, glucagon, epinephrine, lidocaine, enoxaparin sodium, and phytonadione.

We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biosimilar insulin product candidates and proprietary product candidates, which are in various stages of development and target a variety of indications. Four of the ANDAs are currently on file with the FDA.

To complement our internal growth and expertise, we have made several strategic acquisitions of companies, products and technologies. These acquisitions collectively have strengthened our injectable, inhalation, and intra-nasal product technology infrastructure by providing additional manufacturing, marketing, and research and development capabilities, including the ability to manufacture raw materials, API, and other components for our products.

Macroeconomic Trends and Uncertainties

Recent uncertain macroeconomic conditions and worldwide events, including extended periods of heightened inflation, fluctuating interest rates and instability in the financial systems, ongoing geopolitical conflicts such as the Russia-Ukraine and Middle East conflicts, as well as rising healthcare costs continue to pose challenges to our business.

See the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, for further discussion of the potential adverse impact of unfavorable global and geopolitical economic conditions on our business, results of operations and financial conditions.

Recent Developments

BAQSIMI® Acquisition

In connection with the acquisition of BAQSIMI® in June 2023, we entered into a Transition Service Agreement, or the TSA, with Eli Lilly & Company, or Lilly, pursuant to which Lilly agreed, for a period of time not to exceed 18 months to provide certain services to us to support the transition of the BAQSIMI® operations, including with respect to the conduct of certain clinical, regulatory, medical affairs, and commercial sales channel activities. Revenues from the sales of BAQSIMI® under the TSA with Lilly during the transition period were recognized on a net basis, similar to a royalty arrangement. The impact of this revenue recognition method resulted in lower reported revenues relative to the revenue that would have been reported had we recognized gross revenues from sales of BAQSIMI®.

-32-

Table of Contents

Throughout 2024, we assumed distribution responsibilities from Lilly to our customers in the United States, which comprises approximately 80% of BAQSIMI® worldwide revenues, as well as certain other countries. As a result, we started recognizing gross revenues and cost of revenues from the sales of BAQSIMI® in these countries, which is classified as product revenue, net and cost of revenue, respectively on the condensed consolidated statement of operations. The assumption of distribution in countries outside the United States will occur on a country-by-country basis once the marketing authorizations for each territory have been transferred to us, we have set up distribution agreements, and we have obtained sufficient inventory.

For more information regarding our acquisition of BAQSIMI®, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 3. BAQSIMI® Acquisition.”

Business Segments

As of September 30, 2024, our performance is assessed and resources are allocated based on the following two reportable segments: (1) finished pharmaceutical products and (2) Active Pharmaceutical Ingredient, or API, products. The finished pharmaceutical products segment manufactures, markets and distributes BAQSIMI®, Primatene MIST®, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes Recombinant Human Insulin, or RHI API, and porcine insulin API for external customers and internal product development. Information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. Factors used to identify our segments include markets, customers and products.

For more information regarding our segments, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 6. Segment Reporting.”

Results of Operations

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

Net revenues

Three Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Net revenues

Finished pharmaceutical products

$

187,357

$

147,665

$

39,692

27

%

API

 

1,462

 

4,190

 

(2,728)

 

(65)

%

Total product revenues, net

188,819

151,855

36,964

 

24

%

Other revenues

2,395

28,701

(26,306)

(92)

%

Total net revenues

$

191,214

$

180,556

$

10,658

 

6

%

Cost of revenues

Finished pharmaceutical products

$

84,208

$

66,867

$

17,341

 

26

%

API

 

5,065

 

5,286

 

(221)

 

(4)

%

Total cost of revenues

$

89,273

$

72,153

$

17,120

 

24

%

Gross profit

$

101,941

$

108,403

$

(6,462)

(6)

%

as % of net revenues

 

53

%  

 

60

%  

-33-

Table of Contents

The increase in net revenues of the finished pharmaceutical products for the three months ended September 30, 2024 was due to the following changes:

Three Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Finished pharmaceutical products net revenues

BAQSIMI®

$

40,409

$

$

40,409

N/A

Glucagon

26,792

29,514

(2,722)

(9)

%

Primatene MIST®

26,055

24,834

1,221

5

%

Epinephrine

21,341

20,199

1,142

6

%

Lidocaine

15,884

15,522

362

2

%

Phytonadione

11,721

7,449

4,272

57

%

Enoxaparin

5,615

7,702

(2,087)

(27)

%

Naloxone

4,037

4,715

(678)

(14)

%

Other finished pharmaceutical products

 

35,503

 

37,730

 

(2,227)

 

(6)

%

Total finished pharmaceutical products net revenues

$

187,357

$

147,665

$

39,692

 

27

%

Product Revenues, net

Throughout 2024, we assumed distribution responsibilities for BAQSIMI® from Lilly to our customers in the United States, and certain other countries. As a result, $40.4 million of our third quarter BAQSIMI® sales were recognized separate from the cost of revenues, similar to our other products. During the third quarter of 2024, while the Company was transitioning from Lilly labeled product to Amphastar labeled product, our supplier was unable to supply Amphastar labeled product in 14 European countries on a timely basis, which limited sales by approximately $2.0 million to $3.0 million.

For more information, see “Part I – Item 1. Financial Statements – Notes to the Condensed Consolidated Financial Statements – Note 4. Revenue Recognition.”

Primatene MIST® sales increased primarily due to an increase in unit volumes. The increase in sales of epinephrine was primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter. The increase in sales of phytonadione was primarily driven by an increase in unit volume, as a result of an increase in demand. The decrease in sales of glucagon was due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMI®, as well as a decrease in average selling price. The decrease in sales of enoxaparin and naloxone was primarily due to a decrease in unit volumes. The decrease in other finished pharmaceutical products was primarily due to lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels. This decrease was partially offset by higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited, as well as the launch of albuterol in August 2024. Between $2.0 million and $4.0 million in sales expected to be recognized in the third quarter were not recognized due to delayed shipments caused by the aftermath of Hurricane Helene. Revenues for these shipments are expected to be recognized in the fourth quarter.

We anticipate that sales of naloxone and enoxaparin will continue to fluctuate in the future due to competitive dynamics. We also anticipate that sales of epinephrine and other finished pharmaceutical products will continue to fluctuate depending on the ability of our competitors to supply market demands.

Sales of API primarily depend on the timing of customer purchases, and will be lower for the next two years because MannKind, our largest RHI customer, is in the process of qualifying our upgraded RHI, which uses our internally produced inclusion bodies made at AFP. Until they complete this process, we anticipate sales of RHI will be at levels lower than historical.

-34-

Table of Contents

Other Revenues

Other revenues include the portion of BAQSIMI® sales made by Lilly on our behalf under the TSA which amounted to $2.4 million and $28.7 million during the three months ended September 30, 2024 and 2023, respectively, based on total BAQSIMI® sales of $6.4 million and $48.7 million, respectively, as reported to us by Lilly, which was recognized on a net basis, similar to a royalty arrangement. The BAQSIMI® sales made by Lilly on our behalf under the TSA have decreased throughout 2024, due to our assumption of distribution responsibilities for BAQSIMI® from Lilly to our customers in the United States, and certain other countries. We recognized these sales within product net revenues.

Backlog

A significant portion of our customer shipments in any period relate to orders received and shipped in the same period, generally resulting in low product backlog relative to total shipments at any time. As of September 30, 2024, we experienced an immaterial amount of backlog for various products, primarily as a result of competitor shortages and supplier constraints. Historically, our backlog has not been a meaningful indicator in any given period of our ability to achieve any particular level of overall revenue or financial performance.

Gross margins

The decrease in gross margins during the three months ended September 30, 2024, is primarily due to an increase in labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value. As a result of the TSA with Lilly, the portion of revenues relating to BAQSIMI® sales made by Lilly on our behalf are reported on a net basis, similar to a royalty arrangement with no amount reported as cost of revenues. Therefore, in the prior year, BAQSIMI® sales did not have any associated cost of revenues, which increased the gross margins.

The decrease in gross margins was partially offset by an increase in sales of Primatene MIST® and epinephrine, which are higher-margin products.

We are currently experiencing increased costs for labor as well as certain APIs and purchased components. However, we believe that this trend will be offset longer term by increased sales of our higher-margin products, including BAQSIMI®, Primatene MIST®, vasopressin, ganirelix, and albuterol, and new products we anticipate launching.

Selling, distribution and marketing, and general and administrative

Three Months Ended

 

September 30, 

Change

2024

2023

Dollars

%

 

(in thousands)

 

Selling, distribution, and marketing

    

$

8,995

    

$

6,407

    

$

2,588

    

40

%

General and administrative

$

14,821

$

12,654

$

2,167

 

17

%

The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®. The increase in general and administrative expense was primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI®.

We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMI® and Primatene MIST®. Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters.

-35-

Table of Contents

Research and development

Three Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Salaries and personnel-related expenses

$

7,768

$

7,007

$

761

 

11

%

Pre-launch inventory

 

222

 

460

 

(238)

 

(52)

%

Clinical trials

 

9

 

673

 

(664)

 

(99)

%

FDA fees

 

34

 

45

 

(11)

 

(24)

%

Materials and supplies

 

5,852

 

3,664

 

2,188

 

60

%

Depreciation

 

3,278

 

2,452

 

826

 

34

%

Other expenses

 

3,914

 

2,363

 

1,551

 

66

%

Total research and development expenses

$

21,077

$

16,664

$

4,413

26

%

The increase in research and development expenses is primarily due to an increase in expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses. This was partially offset by a decrease in clinical trial expense, due to the timing of clinical trials.

Research and development expenses consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.

Non-operating income (expenses), net

Three Months Ended

 

September 30, 

Change

2024

2023

Dollars

%

 

(in thousands)

 

Non-operating income (expenses)

Interest income

$

2,427

$

1,202

$

1,225

102

%

Interest expense

(6,698)

(13,702)

7,004

(51)

%

Other income (expenses), net

    

(5,094)

    

3,459

    

(8,553)

    

(247)

%

Total non-operating income (expenses), net

$

(9,365)

$

(9,041)

$

(324)

4

%

The change in non-operating income (expenses), net is primarily a result of:

An increase in interest income resulting from an increase in cash and investments.

A decrease in interest expense was primarily due to the $250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of the associated unamortized debt issuance costs related to the Term Loan in 2023.

A change to Other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended September 30, 2024.

-36-

Table of Contents

Income tax provision

Three Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Income tax provision

$

7,254

$

14,025

$

(6,771)

(48)

%

Effective tax rate

15

%  

 

22

%  

Our effective tax rate for the three months ended September 30, 2024 decreased in comparison to the three months ended September 30, 2023, primarily due to differences in pre-tax income positions and timing of discrete tax items. For more information regarding our income taxes, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 15. Income Taxes.”

Beginning in 2024, many countries are implementing some or all of the Organization for Economic Co-operation and Development’s Inclusive Framework on Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countries’ implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.

Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023

Net revenues

Nine Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Net revenues

Finished pharmaceutical products

$

519,147

$

426,541

$

92,606

 

22

%

API

 

6,689

 

11,048

 

(4,359)

 

(39)

%

Total product revenues, net

525,836

437,589

88,247

 

20

%

Other revenues

19,608

28,701

(9,093)

 

(32)

%

Total net revenues

$

545,444

$

466,290

$

79,154

 

17

%

Cost of revenues

Finished pharmaceutical products

$

236,433

$

192,500

$

43,933

 

23

%

API

 

21,804

 

18,809

 

2,995

 

16

%

Total cost of revenues

$

258,237

$

211,309

$

46,928

 

22

%

Gross profit

$

287,207

$

254,981

$

32,226

13

%

as % of net revenues

 

53

%  

 

55

%  

-37-

Table of Contents

The increase in net revenues of the finished pharmaceutical products for the nine months ended September 30, 2024, was due to the following changes:

Nine Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Finished pharmaceutical products net revenues

BAQSIMI®

$

85,106

$

$

85,106

N/A

Glucagon

82,700

82,486

214

0

%

Epinephrine

75,392

57,004

18,388

32

%

Primatene MIST®

73,077

64,837

8,240

13

%

Lidocaine

41,457

43,174

(1,717)

(4)

%

Phytonadione

31,998

33,017

(1,019)

(3)

%

Enoxaparin

17,984

25,441

(7,457)

(29)

%

Naloxone

12,124

14,774

(2,650)

(18)

%

Other finished pharmaceutical products

 

99,309

 

105,808

 

(6,499)

 

(6)

%

Total finished pharmaceutical products net revenues

$

519,147

$

426,541

$

92,606

 

22

%

Product Revenues, net

Throughout 2024, we assumed distribution responsibilities for BAQSIMI ® from Lilly to our customers in the United States, and certain other countries. As a result, $85.1 million of our BAQSIMI® sales for the nine months ended September 30, 2024, are recognized separate from the cost of revenues, similar to our other products.

For more information, see “Part I – Item 1. Financial Statements – Notes to the Condensed Consolidated Financial Statements – Note 4. Revenue Recognition.”

The increase in sales of epinephrine was primarily due to an increase in unit volumes, as a result of an increase in demand caused by other supplier shortages. Primatene MIST® sales increased primarily due to an increase in unit volumes. The decrease in sales of enoxaparin and naloxone was primarily due to a decrease in unit volumes. The decrease in other finished pharmaceutical products was primarily due to lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels, as well as lower unit sales of medroxyprogesterone, as our API supplier discontinued making the active ingredient, which resulted in a halt of sales of medroxyprogesterone after the third quarter of 2023. Subsequently, we qualified our subsidiary, ANP, to manufacture this API, and in September 2024, we re-launched the product. This decrease was partially offset by higher unit volumes of dextrose and sodium bicarbonate due to an increase in demand caused by other supplier shortages, as well as the launch of albuterol in August 2024.

We anticipate that sales of naloxone and enoxaparin will continue to fluctuate in the future due to competitive dynamics. We also anticipate that sales of epinephrine and other finished pharmaceutical products will continue to fluctuate depending on the ability of our competitors to supply market demands.

Sales of API primarily depend on the timing of customer purchases, and will be lower for the next two years because MannKind, our largest RHI customer, is in the process of qualifying our upgraded Recombinant Human Insulin, or RHI, which uses our internally produced inclusion bodies made at AFP. Until they complete this process, we anticipate sales of RHI will be at levels lower than historical.

Other Revenues

Other revenues include the portion of BAQSIMI® sales made by Lilly on our behalf under the TSA which amounted to $19.6 million and $28.7 million during the nine months ended September 30, 2024 and 2023, respectively, based on total BAQSIMI® sales of $38.6 million and $48.7 million, respectively, as reported to us by Lilly, which was recognized on a net basis, similar to a royalty arrangement. The BAQSIMI® sales made by Lilly on our behalf under the TSA have

-38-

Table of Contents

decreased throughout 2024, due to our assumption of distribution responsibilities for BAQSIMI® from Lilly to our customers in the United States, and certain other countries. We recognized these sales within product net revenues.

Gross margins

The decrease in gross margins during the nine months ended September 30, 2024, is primarily due to an increase in depreciation and amortization expenses related to the acquired BAQSIMI® assets, an increase in labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value. As a result of the TSA with Lilly, the portion of revenues relating to BAQSIMI® sales made by Lilly on our behalf are reported on a net basis, similar to a royalty arrangement with no amount reported as cost of revenues. Therefore, in the prior year, BAQSIMI® sales did not have any associated cost of revenues, which increased the gross margins.

The decrease in gross margins was partially offset by the increase in sales of Primatene MIST® and epinephrine, which are higher-margin products.

We are currently experiencing increased costs for labor as well as certain APIs and purchased components. However, we believe that this trend will be offset longer term by increased sales of our higher-margin products, including BAQSIMI®, Primatene MIST®, vasopressin, ganirelix, albuterol, and new products we anticipate launching.

Selling, distribution and marketing, and general and administrative

Nine Months Ended

    

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Selling, distribution, and marketing

$

27,378

$

20,234

$

7,144

    

35

%

General and administrative

$

43,782

$

38,418

$

5,364

 

14

%

The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®. The increase in general and administrative expense was primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI®.

We expect that selling, distribution and marketing expenses will continue to increase due to the increase in marketing expenditures for BAQSIMI® and Primatene MIST®. Legal fees may fluctuate from period to period due to the timing of patent challenges and other litigation matters.

Research and development

Nine Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Salaries and personnel-related expenses

$

23,898

$

21,653

$

2,245

 

10

%

Pre-launch inventory

 

222

 

460

 

(238)

 

(52)

%

Clinical trials

 

292

 

3,430

 

(3,138)

 

(91)

%

FDA fees

 

1,333

 

142

 

1,191

 

NM

Materials and supplies

 

12,334

 

13,556

 

(1,222)

 

(9)

%

Depreciation

 

9,206

 

7,282

 

1,924

 

26

%

Other expenses

 

8,487

 

6,799

 

1,688

 

25

%

Total research and development expenses

$

55,772

$

53,322

$

2,450

5

%

The increase in research and development expenses is primarily due to an increase in salary and personnel-related expenses, as well as an increase in FDA filing fees as we filed the ANDA for AMP-018 in the second quarter of 2024.

-39-

Table of Contents

This was partially offset by a decrease in clinical trials expense, as well as a decrease in materials and supply expense, as a result of a ramp-up of expenses in 2023 for our insulin and inhalation pipeline products.

Research and development expenses consist primarily of costs associated with the research and development of our product candidates including the cost of developing APIs. We expense research and development costs as incurred.

We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business. We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our insulin and inhalation product candidates. These expenditures will include costs of APIs developed internally as well as APIs purchased externally, the cost of purchasing reference listed drugs and the costs of performing the clinical trials. As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.

Non-operating income (expenses), net

Nine Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Non-operating income (expenses)

Interest income

$

8,320

$

3,156

$

5,164

164

%

Interest expense

(23,918)

(17,702)

(6,216)

35

%

Other income (expenses), net

1,125

1,553

(428)

    

(28)

%

Total non-operating income (expense), net

$

(14,473)

$

(12,993)

$

(1,480)

11

%

The change in non-operating income (expenses), net is primarily a result of:

An increase in interest income resulting from an increase in cash and investments.

An increase in interest expense resulting from the Term Loan used to finance the acquisition of BAQSIMI®, as well as the 2029 Convertible Notes, which we entered into in the second half of 2023. For more information regarding our debt, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 14. Debt.”

A change to Other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the nine months ended September 30, 2024.

Income tax provision

Nine Months Ended

 

September 30, 

Change

    

2024

    

2023

    

Dollars

    

%

 

(in thousands)

 

Income tax provision

$

23,674

$

27,160

$

(3,486)

(13)

%

Effective tax rate

 

16

%  

 

21

%  

Our effective tax rate for the nine months ended September 30, 2024 decreased in comparison to the nine months ended September 30, 2023, primarily due to the timing of discrete tax items partially offset by differences in pre-tax income positions. For more information regarding our income taxes, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 15. Income Taxes.”

-40-

Table of Contents

Liquidity and Capital Resources

Cash Requirements and Sources

We need capital resources to maintain and expand our business. We expect our cash requirements to increase significantly in the foreseeable future as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development stage product candidates and pursue strategic acquisitions of businesses or assets. Our future capital expenditures include projects to upgrade, expand, and improve our manufacturing facilities in the United States and China, including a significant increase in capital expenditures over the next few years. We plan to fund this facility expansion primarily with cash flows from operations. We may also become subject to cash obligations of up to an aggregate of $575.0 million that are contingent upon certain net sales milestones related to the BAQSIMI® acquisition. No milestone payments have been made through the date of this filing. Our cash obligations include the principal and interest payments due on our existing loans and lease payments, as described below and throughout this Quarterly Report.

As of September 30, 2024, our foreign subsidiaries collectively held $9.5 million in cash and cash equivalents. Cash or cash equivalents held at foreign subsidiaries are not available to fund the parent company’s operations in the United States. We believe that our cash reserves, operating cash flows, and borrowing availability under our credit facilities will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. We expect additional cash flows to be generated in the longer term from future product introductions, although there can be no assurance as to the receipt of regulatory approval for any product candidates that we are developing or the timing of any product introductions, which could be lengthy or ultimately unsuccessful.

Working capital increased $122.7 million to $386.9 million at September 30, 2024, compared to $264.2 million at December 31, 2023.

Cash Flows from Operations

The following table summarizes our cash flows used in operating, investing, and financing activities for the nine months ended September 30, 2024 and 2023:

Nine Months Ended September 30, 

    

2024

2023

(in thousands) 

Statement of Cash Flow Data:

Net cash provided by (used in)

Operating activities

$

184,362

$

159,639

Investing activities

 

(89,252)

 

(546,067)

Financing activities

 

(47,111)

 

501,176

Effect of exchange rate changes on cash

 

(179)

 

(44)

Net increase in cash, cash equivalents, and restricted cash

$

47,820

$

114,704

Sources and Use of Cash

Operating Activities

Net cash provided by operating activities was $184.4 million for the nine months ended September 30, 2024, which included net income of $121.6 million. Non-cash items comprised primarily of $47.8 million of depreciation and amortization, which includes $21.0 million related to depreciation of property, plant and equipment; $18.5 million related to amortization of product rights, trademarks and patents; $3.0 million related to amortization of operating lease right-of-use assets; $5.3 million related to amortization of discounts, premiums, and debt issuance costs; and share-based compensation expense of $18.7 million.

-41-

Table of Contents

Additionally, for the nine months ended September 30, 2024, there was a net cash outflow from changes in operating assets and liabilities of $6.0 million, which resulted primarily from an increase in accounts receivables, an increase in inventories, as well as an increase in prepaid expenses and other assets, which was partially offset by an increase in accounts payable and accrued liabilities. The increase in accounts receivables was primarily due to the increase in sales. The increase in inventories was primarily due to the increased purchases of certain raw materials and components. Accounts payable and accrued liabilities increased primarily due to the increase in accrued customer fees and rebates associated with BAQSIMI® sales, as we continue to assume distribution responsibilities for BAQSIMI® from Lilly to our customers in the United States and certain other countries.

Net cash provided by operating activities was $159.6 million for the nine months ended September 30, 2023, which included net income of $101.4 million. Non-cash items comprised primarily of $36.5 million of depreciation and amortization, $15.6 million of share-based compensation expense, and an impairment charge of $2.7 million relating to the impairment of the IMS (UK) international product rights. Additionally, for the nine months ended September 30, 2023, there was a net cash inflow from changes in operating assets and liabilities of $2.5 million, which resulted from an increase in accounts payable and accrued liabilities, which was partially offset by an increase in accounts receivables and inventories. Accounts payable and accrued liabilities increased primarily due to the timing of payments. The increase in accounts receivables was primarily due to the timing of the payment from Lilly for BAQSIMI® during the quarter, which was received subsequent to the quarter end.

Investing Activities

Net cash used in investing activities was $89.3 million for the nine months ended September 30, 2024, primarily due to the payment of $129.0 million relating to the BAQSIMI® acquisition, $28.6 million in purchases of property, plant, and equipment, which included $10.2 million incurred in the United States, $2.4 million in France, and $15.9 million in China. This was partially offset by a net cash inflow of $71.0 million from sales and purchases of investments during the period.

Net cash used in investing activities was $546.1 million for the nine months ended September 30, 2023, primarily as a result of $506.4 million relating to the BAQSIMI® acquisition, $28.7 million in purchases of property, plant, and equipment, which included $19.5 million incurred in the United States, $1.7 million in France, and $7.5 million in China.

Financing Activities

Net cash used in financing activities was $47.1 million for the nine months ended September 30, 2024, primarily as a result of $43.5 million used to purchase treasury stock and $8.2 million used to settle share-based compensation awards under our equity plan and for tax payments related to the net share settlement of options exercised. Additionally, we made $8.1 million in principal payments on our long-term debt, primarily as a result of paying off the mortgage loan with East West Bank. This was partially offset by $13.6 million of net proceeds from borrowings on our line of credit in China.

Net cash provided by financing activities was $501.2 million for the nine months ended September 30, 2023, primarily due to our entry into the Credit Agreement with Wells Fargo and the issuance of the 2029 Convertible Notes, which was

partially offset by $268.5 million in principal payments of our long-term debt and $24.6 million in debt issuance cost. Additionally, we received $7.4 million in net proceeds from the settlement of share-based compensation awards under our equity plan, which was partially offset by the $58.4 million used to purchase treasury stock.

Indebtedness

For more information regarding our outstanding indebtedness, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 14. Debt”.

-42-

Table of Contents

Critical Accounting Policies

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies as compared to the critical accounting policies as described in our Annual Report on Form 10-K for the year ended December 31, 2023.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 2. Summary of Significant Accounting Policies”.

Government Regulation

Our products and facilities are subject to regulation by a number of federal and state governmental agencies. The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The Drug Enforcement Administration, or DEA, maintains oversight over our products that are considered controlled substances.

From February 20 through March 1, 2024, our Amphastar facility in Rancho Cucamonga, California was subject to pre-approval and cGMP inspection by the FDA. The inspection included a review of compliance with FDA regulations to support one of our pending applications as well as to compliance with Good Manufacturing Practices. The inspection resulted in several observations on Form 483. We responded to those observations. We believe that our response to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.

From July 15 through July 19, 2024, our Armstrong facility in Canton, Massachusetts was subject to a pre-approval inspection by the FDA. The inspection included review of compliance of our analytical laboratory with FDA regulations to support one of our pending applications. The inspection resulted in several observations on Form 483. We responded to those observations. We believe that our response to the observations will satisfy the requirements of the FDA and that no significant further actions will be necessary.

-43-

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Except for the broad, ongoing macroeconomic challenges facing the global economy and financial markets, there have been no material changes in market risk from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2023. We are exposed to market risk in the ordinary course of business. Market risk represents the potential loss arising from adverse changes in the value of financial instruments. The risk of loss is assessed based on the likelihood of adverse changes in fair values, cash flows or future earnings. We are exposed to market risk for changes in the market values of our investments (Investment Risk), the impact of interest rate changes (Interest Rate Risk), and the impact of foreign currency exchange changes (Foreign Currency Exchange Risk).

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a) to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b) to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

Inherent Limitations of Internal Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

-44-

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For information regarding legal proceedings, see “Part I – Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements – Note 20. Litigation.”

ITEM 1A. RISK FACTORS

Except as noted below, there were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

The facilities we use for our headquarters, laboratory and research and development activities are located in earthquake-prone areas of California. A significant percentage of the facilities we use for our manufacturing, packaging, warehousing, distribution and administration offices are also located in these areas. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. Additionally, we currently rely on third parties whose operations may be disrupted by natural disasters. For example, the aftermath of Hurricane Helene caused us to experience delays in shipments of certain products.

If a natural disaster, power outage or other event occurred that prevented us or the third parties upon whom we depend from using all or a significant portion of our facilities, that damaged critical infrastructure, such as our or third parties’ manufacturing facilities, or that otherwise disrupted operations of ours or those of third parties, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans.

Jack Y. Zhang and Mary Z. Luo have each pledged shares of our common stock to secure funds borrowed under existing credit lines from three financial institutions. Each of the lenders has varying rights as a lender, including one which has the right to conduct a forced sale at its sole discretion. An action by one of the lenders could include a sale of certain shares of our common stock pledged as collateral, the sale of which could cause the price of our common stock to decline. An action to cure and cover indebtedness by any one of the lenders could also have other negative impacts on our business.

Since September 2015, UBS Bank USA, or UBS, has made extensions of credit up to the amount of $8.0 million to Applied Physics & Chemistry Laboratories, Inc., or APCL, which is controlled by Jack Y. Zhang and Mary Z. Luo. In May 2019, the credit amount was increased to $11.0 million. Since February 2017, UBS Group AG, or UBS AG, has also provided an extension of credit up to the amount of $8.0 million to APCL. In 2021, the outstanding UBS AG credit line was transferred to UBS’s Utah location due to an organizational change and in June 2024, the credit line with UBS was increased to $11.9 million. As of September 30, 2024, the total outstanding UBS combined credit lines were $11.9 million. The UBS credit lines are secured by a pledge of 400,000 shares of our common stock currently held by APCL. Interest on the loans accrues at market rates. UBS has an unlimited and unilateral right to call each of the credit lines for any reason whatsoever.

In October 2017, East West Bank, or East West, entered into an agreement with Drs. Zhang and Luo whereby East West would loan them up to $5.0 million. In March 2023, East West amended the loan to increase the loan amount to $8.0 million. As of September 30, 2024, the loan is secured by a pledge of 500,000 shares of our common stock held by Dr. Zhang. Interest on the loan accrues at market rates. East West has acceleration rights to protect itself in the event of a default.

-45-

Table of Contents

In June 2024, Cathay Bank entered into an agreement with APCL and Dr. Luo, whereby Cathay Bank would loan them up to $20.0 million. As of September 30, 2024, the loan is secured by a pledge of 1,000,000 shares of our common stock held by APCL and Dr. Luo. Interest on the loan accrues at market rates. Cathay Bank has acceleration rights to protect itself in the event of a default.

We are not a party to these loans, which are full recourse against APCL and each of Drs. Zhang and Luo, respectively, and are secured by pledges of a portion of the shares of our common stock currently held by APCL and each of Drs. Zhang and Luo.

In 2021, we created a pledging policy to restrict the pledging of shares by our executive officers and directors. The policy prohibits our executive officers and directors from entering into any transaction whereby the executive officer or director, directly or indirectly, pledges, hypothecates, or otherwise encumbers more than twenty (20) percent of shares of common stock held by the individual or more than five (5) percent of our total outstanding shares of common stock as of the date of the transaction, whichever is lower, as collateral for indebtedness. This restriction extends to any hedging or similar transaction designed to decrease the risks associated with holding our securities. For already existing pledges made by executive officers and directors, those existing pledges must be reduced to no more than twenty (20) percent of the shares of our common stock held by such individual as collateral for indebtedness within three (3) years of December 31, 2021. As a result of this policy, Drs. Zhang and Luo reduced their total number of pledged shares to 1,900,000 in June 2024 from 2,350,000 in May 2022, 3,182,898 in February 2022, and 8,582,898 in February 2021.

If the price of our common stock declines, Drs. Zhang and Luo may be forced by these financial institutions to provide additional collateral for the loans or to sell shares of our common stock held by them in order to remain within the margin limitations imposed under the terms of their loans. Furthermore, the pledged shares of our common stock may be acquired and sold by the lenders. These factors may limit Drs. Zhang and Luo’s ability to either pledge additional shares of our common stock or sell shares of our common stock held by them as a means to avoid or satisfy a margin call with respect to their pledged shares of our common stock in the event of a decline in our stock price that is large enough to trigger a margin call. Any significant sales of shares of our common stock by one or more of these three lenders could cause the price of our common stock to decline further.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(c)Issuer Purchases of Equity Securities

The table below provides information with respect to repurchases of our common stock.

    

    

    

Total Number of Shares

    

Maximum Number of

 

Average

Purchased as Part of

Shares that May Yet Be

 

Total Number of Shares

Price Paid

Publicly Announced Plans

Purchased Under the Plans

 

Period

Purchased (1)

per Share

or Programs

or Programs

 

July 1 - July 31, 2024

 

277,955

 

$

39.55

277,955

 

August 1 - August 31, 2024

 

247,158

44.48

 

247,158

 

September 1 - September 30, 2024

 

271,925

47.64

271,925

 

(1)On June 3, 2024, we announced that our Board of Directors authorized an increase of $50.0 million to our share buyback program. As of September 30, 2024, $42.0 million remained available for repurchase under such program. The share buyback program does not have an expiration date.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

-46-

Table of Contents

ITEM 5. OTHER INFORMATION

Securities Trading Plans of Directors and Executive Officers

During our last fiscal quarter, none of our officers or directors, as defined in Rule 16a-1(f), adopted or terminated a Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, each as defined in Regulation S-K Item 408.

ITEM 6. EXHIBITS

Exhibit
No.

    

Description

10.1*

Distribution Agreement by and between Armstrong Pharmaceuticals, Inc. and Hong Kong Genreach Limited, dated August 28, 2024

31.1

Certification pursuant to Rule 13a-14(a) or 15d-14a of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of pursuant to Rule 13a-14(a) or 15d-14a of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1#

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2#

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

101.INS

XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definitions Linkbase Document

104

Cover Page Interactive File (Formatted as Inline XBRL and contained in Exhibit 101)

#

The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.

*

Certain confidential information contained in this exhibit was omitted by means of marking such portions with brackets because the identified confidential information (i) is not material and (ii) is of the type that the registrant treats as private or confidential. In addition, certain schedules (or similar attachments) have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K.

-47-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMPHASTAR PHARMACEUTICALS, INC.
(Registrant)

By:

/s/ JACK Y. ZHANG

Jack Y. Zhang

Chief Executive Officer
(Principal Executive Officer)

Date: November 7, 2024

AMPHASTAR PHARMACEUTICALS, INC.
(Registrant)

By:

/s/ WILLIAM J. PETERS

William J. Peters

Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: November 7, 2024

-48-